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Exactly!” said Deep Thought. ”So once you do
know what the question actually is, you’ll know
what the answer means.
Douglas Adams
The Hitchhiker’s Guide to the Galaxy

ABSTRACT
Impaired wound healing and the resulting chronic wounds may cause
significant morbidity and mortality. In these pathogenic wound envi-
ronments, the ratio of inflammatory and anti-inflammatory cytokines
is highly biased to the pro-inflammatory side. While the inflamma-
tory process is an essential step in healthy wound healing, chronic
wounds remain in a constant self-sustaining state of inflammation.
Thus, decreased cell proliferation, reduced matrix deposition and de-
layed wound closure are the results. Although various cytokine-based
therapies have shown promising results on skin regeneration in prelim-
inary studies, their overall clinical use has been considerably limited by
the short half-life time of the signaling molecules due to rapid dilution
and degradation in the protease-rich chronic wound environment.
In this work, we explored the ability of starPoly(ethylene glycol)-glycos-
aminoglycan (GAG) hydrogels to modulate the hallmarks of chronic
wound development, such as the prolonged inflammation, increased
cell influx and delayed proliferative phase. Therefore, different strate-
gies were developed to shape the cytokine levels in the wound towards
a more pro-regenerative direction, finally promoting the natural repair
process in chronic skin wounds. By biomimetically utilizing the interac-
tions between cytokines and the tissue ECM in a GAG-based biohybrid
hydrogel, we could engineer the concentrations of various signaling
factors involved in the regulation of the repair process.
More in detail, we utilized customized functionalized starPEG-GAG
hydrogels to (1) reduce the extensive levels of inflammatory chemokines
by scavenging them via GAG component of the hydrogel and thus
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diminish immune cell influx in a mouse wound model; (2) locally
deliver the immunomodulatory IL-4 and IL-10 to shift the signaling
balance into the pro-regenerative direction and thus resolve inflam-
mation and (3) administer pre-conjugated transforming growth factor
β (TGF-β) to enhance myofibroblast differentiation and extracellular
matrix deposition. We believe that the presented hydrogel platform
may become a promising tool in the management of cytokines in re-
generative applications, which can be translated towards the clinical use
for the treatment of chronic wounds and other diseases characterized by
uncontrolled inflammation.
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1
INTRODUCTION
1.1 motivation
In his or her lifetime every person will sustain some type of skin
wound. Most of these wounds are caused by smaller injuries and heal
without greater attention. However, an extensive number of people
suffer from chronic wounds with impaired wound closure and often
dysfunctional reparative processes. According to the World Health
Organization, five to seven million chronic and complex wounds occur
in North America alone each year [1]. In general, wounds that do not
heal within three months are considered as chronic. While these non-
healing wounds cause severe pain and impede the patient’s ability to
continue a normal life, they often build the foundation of even more
serious medical complications. Because of the long-term lesion, the
skin can not maintain its natural function as a barrier against chemicals,
pathogens or sunlight. This deficiency can lead to functional limitations
and additional complications such as infections, the development of
malignant carcinoma or eventually limb amputation. As a consequence,
foot ulcers are the most common cause of non-traumatic amputa-
tion [2]. Current therapeutic strategies focus mostly on providing a
favorable healing environment by protecting the wound from further
trauma, while helping to manage moisture and exudate [3]. Although
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the traditional wound treatment can be beneficial for some injuries, it
often fails to induce wound closure, resulting in prolonged discomfort
and impediment for the patient.
1.2 current state of biomaterial-based concepts in
dermal wound healing
For the application as wound dressings biomaterials can be utilized
to provide a barrier between the injury and the external environment
as well as manage the exudate and provide overall beneficial wound
healing conditions [4]. Alginate-based materials for example have
proven their clinical efficiency in the management of wound exudate
as they are able to absorb and store large amounts of wound fluid [5,
6]. Other important dressings to manage wound fluids are hydro-
colloid materials based on higly absorbent polymers such as gelatin,
pectin or carboxy-methylcellulose [7]. While these materials mostly
manage the wound moisture and provide mechanical protection, they
do not directly interact with the wound environment. In contrast,
hydrogel dressings based on collagen protect the injury and in addition
interact with the wound tissue [8]. As one of the major extracellular
matrix (ECM) components, collagen endogenously provides important
signaling cues, such as adhesion sites and binding domains for growth
factors. Moreover, the protein-based biopolymer can shift the prote-
olytic balance in the wound by providing an abundance of proteolytic
cleavage sites and thus drawing proteases away from the degradation of
growth factors [9]. Hyaluronic acid, another component of the ECM
is also widely applied as a wound dressing material due to its high
swelling capability and positive effects on ECM remodeling and cell
proliferation [10, 11]. Aside from the natural biopolymers, synthetic
2
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hydrogels, such as scaffolds based on poly(ethylene glycol) (PEG) or
polyurethane (PU), were developed [4].
A major trend in the conception of advanced wound care materials
care are instructive systems that are capable of accelerating the wound
healing process through the material-based provision of multiple cell-
instructive signals [4, 12, 13]. In consequence, novel therapies have
been developed and made their way into the clinics, ranging from the
application of recombinant growth factors for the promotion of cell
proliferation, such as Becaplermin (Regranex®), to highly sophisticated
cell-based dermal substitutes, such as Dermagraft® [14, 15].
To develop therapies based on the delivery of bioactive molecules,
mainly growth factors have been tested to promote the repair of chronic
wounds [16]. However, due to the highly proteolytic environment
found in the inflammatory wound, these attempts have only shown
limited success. The hostile wound environment diminishes the activity
of growth factors and other signaling proteins, therefore reducing the
bioactivity and overall efficiency of cytokine-based therapies. To coun-
teract the fast degradation, supraphysiological amounts of cytokines are
applied, which can result in a number of unwanted side effects [17–21].
For example Becaplermin, a topical PDGF application for the treat-
ment of diabetic neuropathic ulcers was found to cause increased risk
of malignancy, leading to its withdraw from the European market [22].
Advanced wound care materials might offer an alternative. Thus, cur-
rent strategies to deliver low molecular weight drugs, cytokines and
growth factors utilize various conjugation concepts to immobilize the
active molecule within the material and allow for a subsequent sus-
tained release delivery [19, 23–28]. Examples for the growth factor
delivery systems are the delivery of insulin-like growth factor 1 (IGF1)
from a collagen scaffold for the treatment of diabetic wounds [29]
or the alginate-based delivery of vascular endothelial growth factor
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(VEGF) [30]. Other more sophisticated examples utilized fibrin-based
matrices to deliver VEGF and platelet-derived growth factor (PDGF)
simultaneously to enhance skin repair in diabetic mice [31]. Moreover,
novel stimuli-responsive materials allow for the modulation of the
cytokine release in both space and time [27, 32].
In summary, hydrogel dressings based of various polymeric mate-
rials play a central role in the treatment of dermal wounds. Efforts
in regenerative medicine focus on extending the functionality of the
currently applied materials to enhance and accelerate wound healing.
Therefore, hydrogel materials were engineered to resemble different
characteristics usually found in the ECM, e.g. to support cell survival or
proliferation and even direct cell fate decisions, such as differentiation
or migration. In particular, the controlled delivery of soluble signaling
molecules enables the modulation of a wide variety of cellular responses.
Although wound dressings derived from natural sources can provide
endogenous cell-instructive cues to the wound environment, they suffer
because of their high heterogeneity, mechanical instability and un-
wanted immunogenic side effects [19, 33]. Biohybrid materials offer
a solution by combining the advantages of synthetic polymers, such
as superior mechanical properties and well-defined characteristics, with
the benefits of a naturally derived matrices, as they provide enhanced
biofunctionality and cellular recognition sites. In the context of wound
healing, growth factor-based therapies have shown only limited success
in promoting the formation of new tissue as they do not address
the underlying problem of a prolonged inflammation in the chronic
wound. Therefore, a rational therapeutic strategy must first target
the persistent inflammatory phase before facilitating the body’s natural
repair mechanisms.
4
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1.3 objective
The objective of this study was the development and testing of dif-
ferent strategies to customize in-house developed starPEG-GAG hy-
drogels for the enhancement of dermal wounds with impaired heal-
ing [34–36]. These biohybrid hydrogels, based on their high water
content (>95%) and the low immunogenicity of the polymer precur-
sors, demonstrated excellent compatibility in numerous biomedical
applications ranging from the enrichment of progenitor cells into is-
chemic tissue to the development of new growth factor-based treatment
strategies of Parkinson’s disease and for the sustained delivery of VEGF
to stimulate the angiogenesis in chronic wounds [37–39].
To explore the potential of starPEG-GAG hydrogels in the field of
dermal wounds, three different directions addressing the different stages
of wound healing were pursued:
• Scavenging of inflammatory chemokines to modulate the re-
cruitment of immune cells into the wound
• Functionalization with anti-inflammatory cytokines to pro-
mote the polarization of regenerative (M2) macrophages
• Delivery of cell-instructive growth factors to enhance the pro-
liferation and differentiation of myofibroblasts
To accomplish this, the glycosaminoglycan (GAG) component of the
polymer network based on heparin or selectively desulfated heparin can
be utilized to provide cell-instructive signaling cues (Fig. 1). Previous
studies have shown that the high-affinity interaction between chemo-
kines and GAG components of the tissue ECM is essential for the
chemoattractant activity and consequently for the influx of immune
cells into the wound [40–42]. By providing an excess of chemokine
binding sites in the starPEG-GAG hydrogels, the material might act
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as a sink for these pro-inflammatory chemokines, thus stopping the
recruitment of immune cells into the wound and finally helping to
resolve the inflammatory process.
Scavenging
e.g. MCP-1, IL-8▼
Immunomodulation
e.g. IL-4, IL-10▲
Promote healing
e.g. TGFβ▲
starPEG-GAG
hydrogel
Dermal tissue
Wound
GAGs
e.g. heparin
starPEG
scavenging
delivery
inflammatory
cytokines
regenerative
cytokines
Figure 1 – Overview of starPEG-GAG hydrogels in wound healing applications.
Hydrogels based on GAG and starPEG modulate the wound environment by
the delivery of regenerative signaling cues and the neutralization of inflammatory
cues to engineer the wound environment and facilitate healing.
Moreover, the functionalization of the starPEG-GAG hydrogel with
anti-inflammatory cytokines should promote pro-regenerative macro-
phage subsets, which might support the healing process. For this,
Interleukin 4 (IL-4) and Interleukin 10 (IL-10) can be conjugated into
the hydrogel network during the polymerization process and should
be released to modulate the inflammatory response of immune cells.
Finally, the hydrogel-based delivery of transforming growth factor β
(TGF-β) as a growth factor involved in the recruitment and differentia-
tion of dermal fibroblasts, will be explored as a strategy to deliver growth
factors at physiological levels as opposed to the supraphysiological levels
applied in current clinical treatments. Altogether, the aim of this thesis
project is to further explore the suitability of starPEG-GAG hydrogels
for the modulation of chronic inflammation and promotion of wound
healing.
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FUNDAMENTALS
The act of wound healing is a highly complex, multitemporal, multi-
scale process, involving the combined effort of a wide range of cell
types including keratinocytes, fibroblasts, epithelial cells, macrophages,
platelets, cytokines and molecules of the ECM. During this process,
several key aspects of intercellular communication are employed to
coordinate the common effort to repair the tissue, which when im-
balanced can impair the proceeding of healing and eventually lead to
chronic non-healing wounds. However, to understand the underlying
pathophysiology of chronic wounds, first an understanding of the pro-
cess of acute wound healing is required.
2.1 the physiological process of wound healing
Acute wound healing follows a highly controlled hierarchy of pro-
cesses resulting in the repair of the defect site and the formation of
substituting scar tissue [43]. During the healing process, immune cells
kill intruding microbes, new ECM is produced by fibroblast and other
cell types to replace the damaged tissue matrix, the wound tissue con-
tracts to close the wound and epithelial cells migrate and proliferate over
the newly formed tissue to restore the epithelium [44]. To coordinate
this combined attempt to restore the tissue functionality, the involved
cells secrete growth factors, cytokines and chemokines, which are used
as signaling molecules. These bioactive polypeptides can trigger a wide
range of cell actions, including cell survival, growth, differentiation and
7
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Angiogenesis
Vasodilation Maturation and remodeling
Epithelialization
Coagulation Inflammation
Polymorphonuclear neutrophils predominant Macrophages predominant
Contraction
Vasoconstriction Fibroplasia and granulation tissue formation
minutes
1 2 3 4 5 10 20 30
60 hours
1 2 3 4 5 126
24 48
1 2
days
3 4 5 6
7 14 weeks
1 2 3
7 10
1 2 3 4
months
5 6
12
1 2 3
years
Figure 2 – Timescale of the different phases of wound healing. Schematic
representation of the inflammation (red), proliferation (green) and maturation
phase (blue) with the approximated durations. Adapted from Häggström [47].
control over the migration of their target cell [45]. To achieve this, the
extracellular signal molecules act on paracrine, autocrine, juxtacrine or
endocrine levels and can affect the gene expression, metabolism, cell
shape and migration [46].
Overall, dermal wound healing can be separated into three phases
that overlap in time: inflammation, proliferation and maturation. Dur-
ing the injury of the tissue, blood vessels are disrupted and release
cells and plasma into the open wound cavity. Through coagulation
and resulting formation of a blood clot, the homeostasis of the body
can rapidly be reestablished by the formation of a provisional matrix
based on cross-linked fibrin and other components of the ECM, such
as fibronectin, vitronectin and thrombospondin [48–50]. Platelets
contained in the blood facilitate this process and release several me-
diators through degranulation into the blood clot, such as PDGF,
VEGF, Interleukin 1β (IL-1β) and endothelial growth factor (EGF),
which attract immune cells and fibroblasts into the wound [51]. In
addition, keratinocytes from the disrupted epidermal barrier release
similar growth factors but also inflammatory cytokines, such as tumor
necrose factor (TNF) and IL-1β to attract various immune cells to the
injury [52–55]. Altogether, the cytokines secreted from the blood clot
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and injured cells, diffuse through the surrounding tissue, enabling more
cells to participate in the repair process.
Neutrophils are attracted to the wound bed by inflammatory me-
diators, foremost chemokines, and act there as a first line of defense
against intruding pathogens by releasing preformed granules containing
a mix of proteolytic enzymes (e.g. neutrophil elastase or cathepsin G)
together with large quantities of highly antimicrobial reactive nitrogen
and oxygen intermediates [56]. In addition, these immune cells possess
the ability to ingest microbes and other particles through phagocytosis
to eliminate bacteria, but also to clear damaged cells or denatured
extracellular matrix components from the wound environment [51].
Another supporting mechanism against microbial attacks is the release
of neutrophil extracellular traps (NETs), web-like structures comprised
of DNA and proteolytic enzymes that entrap and kill bacteria [57].
Even more, it prevents infections from spreading by building a tight
physical barrier around the pathogens. With all these tools neutrophils
are able to protect the body from the intrusion of pathogens as the first
line of defense during the early wound healing process.
2.1.1 The role of macrophages in wound healing
Within 48 hours after the injury, the neutrophils are replaced by mac-
rophages as the predominant cell type in the wound (Fig. 2). These cells
are attracted under the influence of chemokines in concert with other
homing factors from the bloodstream as undifferentiated monocytes,
which develop into macrophages in the target tissue [58]. Similar to
the neutrophils, macrophages have the ability to phagocytose bacteria
and tissue debris. However, the functional spectrum of macrophages
during wound healing is much more versatile and has not yet been
fully understood. Depending on the microenvironmental signals mac-
rophages are able to switch between several functional subsets, acting in
9
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response to the current requirements in the healing wound [59] (Fig. 3).
On activation with interferon gamma (IFN γ) together with inflam-
matory cytokines (e.g. TNF or IL-1β), or with microbial products
(e.g. lipopolysaccharide (LPS) or CpG DNA fragments), they become
inflammatory macrophages referred to as classically activated orM1. In
this polarization state, cells are characterized by the high expression of
pro-inflammatory cytokines and chemokines, the high production of
toxic intermediates (e.g. nitric oxide or reactive oxygen intermediates)
for microbial defense and their high capacity to present antigens to
other immune cells [59]. This set of actions enables the macrophages to
support the neutrophils in their microbicidal activity and is of particular
relevance in the early stages of acute wound healing.
Tissue macrophages
Classically activated
macrophage
Wound-healing
macrophage
Regulatory macrophage
● microbiocidal activity
● matrix degradation
● generation of pro-inflammatory 
   cytokines & chemokines
● matrix synthesis & stabilization
● generation of growth factors & 
   regenerative chemokines
● generation of anti-inflammatory 
   cytokines
IFNγ
LPS IL-4 IL-13
IL-10
glucocorticoids
apoptotic cells
TNF
Figure 3 – Macrophage subtypes with their polarization signals and functional
role during wound healing. Adapted fromMosser and Edwards [60]. Copyright
permission granted by Nature Publishing Group.
In contrast, the activation of macrophages with Interleukin 4 and
Interleukin 13 results in a functionally different phenotype referred
to as wound-healing macrophages or M2a. They express only low
amounts of pro-inflammatory cytokines but release various growth
factors (e.g. EGF, VEGF, PDGF, TGF-β), therefore, contributing
10
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to the process of wound resolution, as well as promoting angiogenesis,
matrix regeneration and cell proliferation [61–63]. The source of the
IL-4 and Interleukin 13 (IL-13) can originate from various innate
immune cells including lymphocytes, basophils, mast cells and even
macrophages themselves [64, 65]. A third macrophage subset (M2c)
is stimulated by IL-10 or TGF-β and acts immunoregulatory on its
environment.
Due to their extensive phenotypic plasticity and variety in their func-
tional repertoire, macrophages play a major role in the coordination of
the wound healing process. They are able to integrate different signals
from their microenvironment as well as soluble factors released from
ambient cells into their functional response. Therefore, they act as a
central hub in the wound environment, orchestrating the transition
from inflammation to proliferation in a combined effort with their
environment. In addition, macrophages do not differentiate terminally,
but adapt their behavior according to time and the requirements of
their environment. In the early phase of inflammation, macrophages
facilitate the microbial defense through the release of nitric oxide or
reactive oxygen intermediates. Besides their active defensive mecha-
nisms, macrophages release chemokines (e.g. monocyte chemoattrac-
tant protein 1 (CCL2) (MCP-1) or Interleukin 8 (IL-8)) to attract more
immune cells in the wound and inflammatory cytokines to activate
them. Conversely, later in wound healing process, macrophages release
a number of growth factors such as EGF, PDGF and TGF-β to attract
fibroblasts and endothelial cells, increase their proliferation and as a
result, promote the formation of new tissue. Additionally, the release
of VEGF in concert with PDGF enables angiogenesis, the formation
of new blood vessels. Another important quality is their expression
of anti-inflammatory cytokines (e.g. IL-10) as well as decoy receptors
for the suppression of inflammatory signaling during the late stages of
11
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the repair cycle. Moreover, these cells do not only enable the healing
process of the injured tissue, but they also actively contribute to the
production of new ECM molecules, such as collagen, fibronectin or
tenascin C [66].
Taking all these functions into account, it exemplifies the crucial
role of macrophages during wound healing and their essential role in
the transition from inflammation to the phase of tissue proliferation.
This wound healing stage starts with the proliferation and migration of
keratinocytes and other epithelial cells from the edges of the wound to
its center, followed shortly after by the proliferation of fibroblasts from
the surrounding tissue [67, 68]. Restructuring on a cellular level, in
particular, the dissolution of cell-cell and cell-substrate contacts allow
the epithelial cells to migrate freely from the wound edges [45, 69].
Driven by a combination of growth factors, such as fibroblast growth
factor 2 (FGF-2) or PDGF and the absence of cell contact inhibition at
the free wound edges, the proliferating epithelium starts to dissect the
wound by migration between the viable tissue and the blood clot. To
penetrate the tight fibrin matrix, specific proteases for the remodeling
of ECM molecules matrix metalloproteinases (MMPs) are released.
2.1.2 The role of fibroblasts in wound healing
At the same time wound fibroblast attracted largely by PDGF and
FGF-2 also migrate from the adjacent intact dermis into the provisional
matrix, formed by the fibrin-rich blood clot (Fig. 2). The broad set of
cues from local cytokines, e.g. PDGF and FGF-2 support proliferation
and differentiation of these cells, respectively [70, 71]. In the wound,
dermal fibroblasts start to deposit significant amounts of extracellu-
lar matrix components, such as collagen type I and fibronectin [63,
72]. The resulting granulation tissue is characterized by its granular
appearance due to the massive amount of newly formed capillaries [73].
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Because of the low oxygen tension in the new tissue in combination
with the presence of growth factors, foremost VEGF, endothelial cell
are stimulated mitogenically and migrate into the newly formed matrix
for its revascularization [49].
Next to their essential capacity of synthesizing extracellular matrix
components, the dermal fibroblast can differentiate into a contractile
phenotype in response to mechanical stress and TGF-β. These my-
ofibroblasts are characterized by their cytoplasmic microfilamentous
apparatus composed of actin and myosin [72], which enables them
to exert a contractile force in the granulation tissue to facilitate rapid
wound closure. To enable this phenomenon, intracellular stress fibers
are connected via integrins on the cell surface to the ECM by a special-
ized adhesion complex called fibronexus. This devicemediates a durable
continuity between intracellular contractile filaments and extracellular
matrix molecules. Furthermore, the connection of myofibroblast by
gap junctions, allows these cells to form multicellular contractile units
able to collectively contract and sustain the contractile force over an
extended period of time [68, 73]. The granulation tissue starts to
disappear with the end of the epithelialization, caused by a massive
apoptosis of tissue fibroblasts [74]. It is replaced by a framework of
collagen and elastin fibers, which are later saturated with proteoglycans
and glycoproteins of the ECM. Subsequent slow tissue remodeling
of the resulting scar by fibroblasts and other cell types aims to restore
normal tissue architecture, a process that can continue for month and
years (Fig. 2) [75].
13
fundamentals
2.1.3 The role of cytokines and their interaction with the ECM
As indicated in the previous sections, all stages of the repair process are
coordinated by the spatiotemporal action of a wide variety of different
cytokines including various growth factors and chemokines.
They often cover overlapping functions in the wound healing context,
which complicates the exact elucidation of their role in the repair
process. Nevertheless, a large number of important signaling factors
could be identified over the years of research (Tab. 1).
Table 1 –Overview of themajor growth factors, cytokines, chemokines and their
respective role in wound healing. * indicates effects at low concentrations only.
Adapted from Barrientos et al. [63] supplemented with [51, 67, 76]. Courtesy
of John Wiley and Sons.
Growth Factors
Name Source Function
EGF Platelets
Macrophages s Reepithelialization
Fibroblasts
FGF-2 Keratinocytes
Mast Cells s Granulation tissue formation
Fibroblasts s Reepithelialization
Endothelial cells s Matrix formation and remodeling
Smooth muscle cells
Chondrocytes
TGF-β Platelets t Inflammation
Keratinocytes s Granulation tissue formation
Macrophages s Myofibroblast differentiation
Lymphocytes s Matrix formation and remodeling
Fibroblasts s Reepithelialization
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PDGF Platelets s Immune cell influx
Keratinocytes s Granulation tissue formation
Macrophages s Matrix formation and remodeling
Endothelial cells s Reepithelialization
Fibroblasts
VEGF Platelets
Neutrophils s Granulation tissue formation
Macrophages s Angiogenesis
Endothelial cells
Smooth muscle cells
Fibroblasts
Inflammatory cytokines
IL-1β Neutrophils
Monocytes s Inflammation
Macrophages s Reepithelialization *
Keratinocytes
IL-6 Neutrophils s Inflammation
Macrophages s Reepithelialization *
TNF Neutrophils s Inflammation
Macrophages s Reepithelialization *
Anti-Inflammatory cytokines
IL-4 Lymphocytes t Inflammation
Neutrophils s Matrix formation and remodeling
Mast cells
IL-10 Macrophages t Inflammation
Keratinocytes t Immune cell influx
Endothelial cells
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Chemokines
MCP-1 Fibroblasts
Macrophages s Immune cell influx
Neutrophils
IL-8 Fibroblasts
Keratinocytes s Immune cell influx
Macrophages s Reepithelialization *
Neutrophils
SDF-1α Endothelial cells s Angiogenesis
Fibroblasts s Reepithelialization
While these small signaling proteins enable the communication between
cells, they also facilitate the interaction between cells and their non-cellular
microenvironment, the ECM. Cytokines, such as FGF-2 or PDGF induce
the matrix production and deposition in fibroblasts. In turn, a large number
of ECM macromolecules are able to bind and release cytokines and therefore
modulate their availability or activity. This causes a reciprocal interaction
between ECM and the cytokines released by the cells indispensable for the
coordination of the wound healing process [49, 77]
The ECM itself is a mash work of fibrillar proteins (e.g. collagen I, elastin),
proteoglycans (e.g. heparan sulfate), other polysaccharides (e.g. hyaluronic
acid) and soluble factors, altogether providing a fill material for the void
between all cells in the tissue. Besides its structural function the ECMprovides
a number of crucial qualities for the coordination of wound healing: First, the
biomolecules of ECM act as a reservoirs for growth factors by retaining them
in the local tissue and stabilizing them against proteolytic degradation. For
example, VEGF165 binds with high affinity to heparan sulfate containing
proteoglycans [78], which enables the ECM to bind the cytokine and only
slowly release it over time. In contrast, specific proteolytic enzymes, such
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as plasmin are able to cleave the heparin-binding domain from the cytokine
during the early stages of wound healing and, as a result, induce a rapid release
of the VEGF allowing for sustained vascular recruitment during angiogenesis.
Second, binding to the ECM glycosaminoglycans, such as heparan sulfate,
is essential for the functionality of chemokines. This high affinity interaction
enables the generation of stable long ranging gradients that efficiently control
activation andmigration of immune cells in an inflammatory context [41, 79].
Without the complexation to the biopolymers, chemokines would diffuse
from their source tissue and consequently would not be able to build up the
required concentrations to activate the immune cell influx.
Third, the interaction of cell surface receptors for ECM components, the
integrins, directly alter cellular behavior, such as cell viability and proliferation.
The intracellular adaptor proteins of the integrin receptors allow the cells to
transduce extracellular matrix signals into their migration behavior and gene
expression. Moreover, the integrin-matrix interaction can guide the invasion
of capillary sprouts enabling neovascularization of the tissue [80, 81].
Last, a class of degraded ECM components termed matrikines are able to
directly activate cell surface receptors that belong to the cytokine, chemo-
kine or growth factor receptor family [82]. Therefore, Swindle et al. [83]
could demonstrate that a proteolytically cleaved domain of tenascin C, a
glycoprotein found in early wound healing, is able to bind and activate the
EGF receptor (EGFR). This phenomenon offers an interesting implication,
as a large number of matrix components have to be broken down during
wound repair byMMPs or other proteases and thus, might activate cell surface
receptors to modulate the wound healing response.
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2.2 the pathophysiology of chronic wounds
Although extensive research helped to understand important key features
of acute wound healing physiology, for chronic wounds the exact cause
and underlying mechanisms remain largely unsolved. Most chronic dermal
wounds occur in the lower extremities, with 70% of the ulcers being caused
by ischemia, closely followed by diabetes mellitus and pressure sores [2, 3,
84]. Several risk factors for the development of chronic wounds have been
identified, such as old age, obesity, metabolic disease, immune suppressive
medication, inflammatory drugs and stress.
Chronic
● Low mitogenic activity
● Excessive MMPs
● ECM degradation
● Uncontrolled inflammation
● Delayed healing
Acute
●
 High mitogenic activity●
Normal MMP/TIMP ratio● 
Net ECM deposition● 
Self-limiting inflammation
● Normal healing time
Figure 4 – Comparison of acute and chronic wound healing. Adapted from
Mosser and Edwards [60]. Copyright permission granted by Nature Publishing
Group.
In comparison, the chronic wound development differs markedly from
the acute wound healing in a number of key facts (Fig. 4). While in
the acute wound healing the inflammation is decreasing within a few days
after the injury, it persists in chronic wounds with highly increased numbers
of neutrophils and macrophages remaining in the wound environment for
weeks [44, 85, 86]. The greater number of immune cells goes hand in hand
with an increased number of inflammatory cytokines and chemokines, which
in turn attract even more immune cells into the wound [87]. Conversely,
the amount of decoy receptors employed by immune cells to limit the effects
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of inflammatory cytokines is strongly reduced in chronic wounds [51]. Infec-
tions commonly found in the open lesions further contribute to the prolonged
inflammation by alarming immune cells and eliciting further inflammatory
responses. The resulting continuous cycle impairs the resolution of the inflam-
mation and therefore the progression of the wound into a healing stage [86].
Besides the constant inflammation, the large amounts of tissue degrading
proteases (e.g. elastase or MMPs) and reactive oxygen and nitrogen inter-
mediates released by the immune cells can be found in the chronic wound.
In contrast, the amount of protease inhibitors, such as tissue inhibitor of
metalloproteinase (TIMP), commonly found in the acute wound milieu,
is largely decreased, resulting in a highly proteolytic environment [2, 88,
89]. Additionally, growth factors secreted from fibroblast and other cells
are rapidly degraded and in consequence fail in promoting the formation of
new soft tissue [90]. Together with the decreased levels of growth factors and
consequently the overall loss of mitogenic activity, the high levels of MMPs
degrade the ECM components, thereby damaging wound area even further.
Altogether, the combination of excessive inflammatory signaling together
with an increased proteolytic environment keeps the wound in a constant self-
reinforcing feedback loop of persistent inflammation and therefore, impairs
further healing.
2.3 strategies for treatment of chronic wounds
Current therapies of chronic wounds with different etiologies rely on a
treatment strategy known by the acronym TIME [91, 92]. First, necrotic
tissue (T) is removed from the wound either by surgical or enzymatic forms
of debridement. Subsequently, infections and inflammation (I) are medically
treated to prepare the wound for the wound dressing, carefully selected to
balance the moisture (M) in the wound. Finally, epithelialization (E) is
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promoted by additional therapies, such as the application of growth factor
to facilitate the wound closure.
Advances in biotechnology, material science and medical research enabled
the development of new treatment strategies over the last decades, summarized
in the emerging area of regenerative medicine. Therefore, wound dressings,
besides offering a beneficial environment by providing moisture and absorb-
ing exudate, were developed to incorporate additional biological activities
to enhance healing outcomes. As a result, materials displaying different
properties such as antimicrobial activity, the guidance of cell migration to
the material or stimulatory effects on cell proliferation and matrix deposition
have been developed. Most of their biological activities rely on the delivery of
recombinant growth factors to counteract their reduced concentrations found
in chronic wounds. With the absence of cell proliferation and reduced matrix
deposition in the chronic wound milieu, it is not surprising, that recombinant
human PDGF-BB (Becaplermin) was the first FDA-approved growth factor
in 1997 for the treatment of diabetic foot ulcer [93]. Other examples of
growth factor therapeutics have been developed based on FGF-2, fibroblast
growth factor 7 (FGF-7) and VEGF [3]. Although the delivery of growth
factors can be applied to improve wound healing, often supraphysiologically
high doses have to be used to achieve the desired effect [17, 19]. The strongly
proteolytic environment found in chronic wounds rapidly degrades growth
factor therapeutics and therefore decreases their drug efficacy.
Furthermore, viral and non-viral gene therapeutic approaches have been
tested employing gene delivery to increase growth factor expression in situ
and therefore alter the wound environment. Such treatment strategies would
overcome problems with growth factor stability as they produce a constant
expression of the signal proteins in the wound bed. However, these systems
often suffer from low transfection efficiency, variable durability of gene ex-
pression, possible mutations due to the gene integration and adverse immune
reactions in some cases [84, 94, 95].
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A different strategy for the treatment of chronic wounds has been devel-
oped by the application of artificial skin substitutes, which are composed
of various degradable polymer scaffolds combined with dermal or epidermal
cell layers [33]. Most of these substitutes do not survive indefinitely, but
rather provide protection in combination with growth factors and a beneficial
healing environment to the wound tissue [43]. A major drawback for these
therapies is the complex production of skin substitutes, short shelf life and
the immense costs involved. Often several repeated applications are required
to yield the intended healing results. Moreover, if autologous patient-derived
cells, which are the basis for one of the most successful FDA-approved skin
substitutes Apligraf, are used the culturing time for the substitute can take
weeks up to several months until the final therapeutic effect gets realized [96].
Finally, there are no models of bioengineered skin currently available that
completely replicate the anatomy, stability, physiology or aesthetic nature of
unwounded skin.
In summary, the traditional chronic wound therapy relies primarily on
the protection of the injury and the optimization of the wound healing
environment. Yet, for many wounds, this is not sufficient to promote healing
and eventually wound closure. Novel approaches utilize the mitogenic effects
of growth factors to stimulate cell proliferation, although often high doses are
obligatory to yield satisfactory healing results. Additionally, gene therapy and
skin substitutes, although beneficial in the treatment of some chronic wounds,
may further increase the risk of unwanted side effects and overall cost of the
therapy. An alternative is represented by the material-based approaches to
modulate the wound environment described in the following section. Herein,
materials with endogenous anti-inflammatory effects are employed to deliver
low doses of growth factors and other cytokines sustainably at physiological
levels over extended durations of time.
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2.4 biomaterials in medicine
From the definition employed by the American National Institute of
Health, biomaterials are ”any natural or synthetic material (including polymer
or metal), which can be used for any period of time, which augments or replaces
partially or totally any tissue, organ or function of the body, in order to maintain
or improve the quality of life of the individual” [97]. This covers a wide
range, from the traditional implants such as joint replacements or heart valves
to the more sophisticated devices such as drug delivery systems or artificial
tissues [98] (Fig. 5). From the early beginnings of civilization, biomaterials
were used to physically replace any tissue which had been damaged by trauma
or disease (Fig. 5). Thus, the first documented uses were gold and ivory for
replacements of cranial defects used in ancient Egypt and Rome. Develop-
ments in the more recent history include the use of polymethyl methacrylate-
based intraocular lenses or bone replacements during World War II [99].
In these early biomaterials, the selection of the material was based solely
on their physical properties and low toxicity. Hence, based on the leap in
biological and medical research, the clinical demand for biofunctionality and
tissue integration has grown. With the recognition of the importance of the
interactions between materials and the cells in the living tissue, new bioactive
materials were developed that could responsively react to their environment
as well as provide signaling cues to the host tissue.
2.4.1 Polymers in medicine
In modern biomedical applications, hard biomaterials are mostly used in a
load-bearing context such as orthopedic implants (e.g. joint replacement or
internal fixations of fractures). Since the design of metal implants, the toolbox
of materials for medical devices has increased immensely. Today polymers
are the most widely used material in biomedical applications. Soft polymer-
based materials offer new opportunities in tissue engineering of soft tissue like
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Breast implant
Catheter 
Dental implant
Cochlear implant
Bone cement
Artificial tendon
Bone fixation
Heart valve
Intraocular lens
Contact lens
Pacemaker
Stents
Skin substitutes
Hernia mesh
Sutures
Hemodialysis
platinum, silicone
silicone
ceramin, metal
silicone
PTFE, PU
silicone
PTFE, PP
collagen, silicone
metal, PLA
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metal, carbon, 
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Figure 5 – Overview of devices and their materials used in biomedical applica-
tions. Please refer to the list of abbreviations for the definition of the material
name acronyms.
heart, liver or breast [100]. Most importantly hydrogels found their way into
modernmedicine for applications such as contact lenses, drug delivery systems
or wound dressing materials [12, 101]. These water-swollen gels are based
on interconnecting networks of hydrophilic polymers with different types of
covalent or non-covalent cross-linking, as well as physical entanglement [102,
103]. In tissue engineering hydrogels are commonly used as transient artificial
ECM as they were designed to mimic a number of key features typically
provided by the tissue matrix: thus, hydrogels can offer mechanical support
for extended time periods, they can be engineered to be biodegradable and,
due to their structure and high water content, allow for free diffusion of
nutrients and metabolites, which is essential for the support of long-term
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tissue viability [12, 100, 101, 104]. In addition, these materials can be further
engineered to provide specific biofunctionality to the surrounding host tissue.
Over the years, different sources of polymeric materials have been used
in the development of hydrogels and similar polymer-based materials. They
can be either derived from natural sources (e.g. collagen, elastin, silk, cel-
lulose), from synthetic origin (e.g. PEG, silicon, teflon) or derived from
semi-synthetic (hybrid) materials (e.g. by the incorporation of peptide linkers
or proteins into a synthetic material) [98, 100, 105]. Nature-derived poly-
mers offer a broad range of different properties and characteristics depending
on their source and composition. They can originate from different living
organisms such as collagen from animal tissue, cellulose from plant fibers
or bacteria, such as the mixture of exopolysaccharides found in microbial
biofilms. While natural polymers offer a broad range of physical properties
and possess endogenous biological functionalities, their use includes a number
of drawbacks, which complicates their use for medical application. Due to
the variation in their natural source, the properties of derived biomaterials
tend to exhibit a higher heterogeneity, when compared to these based on
fully synthetic polymers. Their complex nature increases the risk of adverse
immune reactions against thematerial when implanted and could additionally
allow for disease transmission from the material source [106]. In contrast,
synthetic polymers offer a high control over the material characteristics and
tissue response. Moreover, their potential immunogenicity is much lower
due to their less complex structure, resulting in the utilization of polymers
like PEG for the decrease of the immunogenic potential of drugs. As such
synthetic polymers offer a set of interesting features for the use in biomedical
applications [19, 33]. However, they are missing any biological functionality,
which is essential for the long-term integration into the tissue. As a solution
to this absence a number of biomaterials were designed in the recent years,
which possess nanoscale features in order to emulate one or several biological
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features of the ECM. Therefore, the synthetic systems were combined with ap-
propriate user-orchestrated biological signals based on incorporating biologic
moieties into otherwise inert polymer materials [103]. The following sections
will describe the incorporation of some essential material characteristics and
their relevance for enabling the interaction of the material with the living
matter:
2.4.2 Mechanical properties
Cells are able to sense their environment in a number of different channels
and respond to the perceived information. One of these environmental
characteristics of particular significance during the design of a biomaterial is
the material stiffness. As different tissues in the body have different elasticity
according to their functional needs, it has been shown, that cells preferentially
differentiate on substrates matching themechanical properties of their endoge-
nous tissues [107, 108] (Fig. 6). Themechanism that enables cells to sense the
stiffness of a substrate originates from cell attachment and the pulling on their
surroundings. This ability is based on their actin-based cytoskeleton in concert
with the cellular myosin-based contractile apparatus [107, 109]. As described
earlier, cells are able to attach to the biomacromolecules of the ECM through
integrins, a group of transmembrane receptors, which bridge the environment
to the inside of the cell [81] (Fig. 7). Through a set of adapter molecules, the
integrin receptor is connected to the actin cytoskeleton, allowing for motility,
cell spreading and other structural responses. Moreover, the integrins are
connected to activator proteins of the Ras superfamily known to regulate
the structure of the cytoskeleton, cell growth, and gene transcription and can
therefore confer the material properties into a cellular response [107] (Fig. 7).
Examples of the importance of durataxis, the response of cells to the stiffness
of their surroundings, can be found in a number of the different cell types
and tissues [112]. Most prominent is the effect of the biophysical cues on the
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Figure 6 – Elasticity of various tissues corresponding to the mechanical prop-
erties of a hydrogel. StarPEG-heparin hydrogels were used as an exemplary
material with adjustable stiffness according to the degree of cross-linking (γ) of
the material [36]. Data for tissue elasticity are based on Butcher, Alliston, and
Weaver [110] and Levental, Georges, and Janmey [111]
differentiation of mesenchymal stem cells (MSCs), which can be controlled
with the modulation of the stiffness of their substrate [113]. While rigid
matrices induce a myogenic or osteogenic phenotype, soft matrices result
in neurogenic differentiation. Consequently, the differentiation of these
cells in the body might be determined by the stiffness of the surrounding
tissue, which elastic modulus (Young’s modulus) ranges from 100 Pa for soft
tissues like brain or lung to 30 GPa for hard tissues like calcified bone [110,
111] (Fig. 6). Another example can be found in the striation of actomyosin
in myotubes, which only emerges on substrates with stiffness typical for
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normal muscle [108]. As for the context of wound healing, it has been
demonstrated that fibroblast and epithelial cell motility and spreading depend
on the substrate elasticity [114].
Several strategies have been developed to adjust the material bulk stiffness to
the specific biomedical application including the variation of the solid content
or the modulation of the number of cross-links in the material. Therefore,
different methods were proposed to adjust material stiffness as an important
parameter for the cellular response. Moreover, another key aspect in the
material development is the difference between the mechanical properties of
the scaffold in bulk and on the micro-scale level. Material heterogeneities
might be perceived by cells, which are only sensing on the microscale level, as
softer or hardermaterials and do notmatch the actual bulk stiffness. Therefore,
different techniques to analyze themechanical propertymight provide a global
picture of the material stiffness [115].
2.4.3 Cellular adhesion
Cellular adhesion on the biomaterial is the basis for cell survival, migration,
proliferation and differentiation. Consequently, it is essential for the inte-
gration of biomaterials into the tissue and thus ensures the long-term perfor-
mance of medical devices. The interaction between anchorage-dependent cells
and their substrate is based on various adhesion domains, which can be found
on almost any ECM molecule (Fig. 7). Hence, materials based on natural
biopolymers such as collagen, fibrin or dextran inherently enable cell adhesion.
However, their pleiotropy of endogenous epitopes can obstruct the study and
modulation of isolated signaling cues might interfere with the development
of a controlled material [116]. Synthetic polymers by their hydrophilic
nature exhibit minimal protein adsorption, which in turn prevents matrix
- cell interaction [104]. In consequence, strategies had to be developed to
incorporate adhesion features into synthetic polymer networks, leading to
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the development of biohybrid hydrogels. For the incorporation of adhesion
linkers, a number of approaches have been presented, including adsorption
onto the polymer or covalent conjugation, which allows amuch higher control
over quantity and morphology of the adhesion ligands presented [117].
Hydrogel
Engineered ECM fragment
Integrin-binding
domain
Growth factor 
binding domain
P
P
P
P
P
P
Integrin cluster
Host cell surface
Src
FAKP
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Cell response
Figure 7 – Cellular interaction with biofunctional recognitions sites on the
material surface. Cells interact with integrins with adhesion domains or via cell
surface receptors with cytokines represented by the growth factor. Adapted from
Rice et al. [19]. Copyright permission granted by John Wiley and Sons.
The RGD tripeptide domain, ubiquitous in a high number of ECM pro-
teins including fibronectin, vitronectin, fibrinogen and collagen, was one of
the first adhesion ligands utilized in biomaterials [118]. Since then, more
adhesion peptides with different effects on specific aspects of cellular behavior
have been identified [119, 120]. The importance of adhesion ligands has been
demonstrated in a number of groundbreaking cell biological experiments:
Therefore, a biphasic relationship between the total RGD concentration and
the speed of cell migration could be observed on RGD-functionalized model
substrates [116]. In addition, spatially controlled presentation of adhesion
peptides, such as clustering or specific spacing, were also demonstrated to
affect cellular responses such as adhesion or motility [121].
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2.4.4 Interaction with cytokines
Besides covalently bound signal motives on the surface of biomolecules,
a large number of soluble signal mediators are used in the communication
between cells in the tissue (Fig. 7). As discussed earlier, cells use polypep-
tide macromolecules to communicate with each other. These cytokines and
growth factors can trigger a wide range of cellular actions, including cell
survival, growth, differentiation and control over the migration of their target
cell [45]. Due to their critical role in controlling basic cellular functions and
their ability to induce and coordinate tissue regeneration, a broad range of
growth factors have been tested for biomedical applications [26]. A critical
issue in their therapeutic application is the low bioavailability and short half-
life [122] caused by the ubiquitous levels of proteases found in nearly all
tissues. Consequently, the large doses of soluble growth factors that are often
required to induce the desired local effect, can result in serious side effects.
For example, delivery of supraphysiological doses of VEGF, a growth factor
essential for angiogenesis and wound healing, may cause unwanted effects
such as neovascularization of non-target tissues and tumor growth [18, 123].
Moreover, Becaplermin, PDGF-based drug discussed earlier in this section,
was removed from the European market due to risk of malignancy formation
as a response to the extensive amounts of mitogenic signaling molecule.
To address this challenge, material-based delivery strategies have been de-
veloped based on the coupling of growth factors to the polymer material [23–
28, 120] (Fig. 8). The primary aim is to enable materials to controllably
release bioactive cytokines at physiological levels over an extended period of
time to elicit the desired therapeutic effect. Early approaches utilized the
modification of the cytokines with various functional groups including thiol,
glutamine, acrylate, and azide, to directly cross-link the signaling proteins into
the material [124–128]. Unfortunately, the modification and cross-linking
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Figure 8 – Strategies to incorporate cytokine and cytokine affinity into the
hydrogel networks. Adapted fromRice et al. [19]. Copyright permission granted
by John Wiley and Sons.
of growth factor often resulted in a decreased bioactivity as the additional
functional groups might sterically interfere with the receptor binding [120].
Furthermore, the method of introducing covalent linkage potentially damages
the growth factors through unspecific side reactions, resulting in a decrease in
overall activity. To overcome the number of problems related to the direct
tethering, other strategies inspired by the interactions between cytokines
and the ECM have been developed. The ECM is able to influence cellular
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signaling by sequestration, stabilization or the triggered release of cytokines
based on their electrostatic interaction with matrix GAGs (Fig. 7). One
of the best-studied examples is the interaction between FGF-2 and heparan
sulfate (HS), which influences growth factor stability and activity in the body.
Under physiological conditions, the sulfate and ester groups of the HS are
deprotonated and therefore able to interact with the positive surface charge
of the FGF-2 (Fig. 9). This positive surface charge, based on an abundance
of basic amino acids, such as histidine, lysine or arginine, can be found on a
large number of growth factors, such as PDGF, TGF-β, some forms of VEGF
and many other signaling proteins [129, 130]. Moreover, a large number
of growth factors include specific binding domains for negatively charged
GAGs such as heparin, heparan sulfate, dermatan sulfate and chondroitin
sulfate [131].
Heparin FGF-2electrostaticinteraction
Figure 9 – Rendering of the electrostatic interaction of FGF-2 and heparin based
on the structural model published by Schlessinger et al. [132] (PDB:1FQ9).
Positive charge is depicted as blue and negative charge as red on the solvent-
accessible surface of the protein.
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The interaction of the ECM with cytokines and other growth factors can
therefore effectively modulate cellular growth, development, angiogenesis,
and tissue regeneration [133]. A number of strategies have been deployed to
utilize this interaction for therapeutic delivery: therefore GAG components
of the ECM have been incorporated into biomaterials through strategies
including carboxyl-amine conjugation [34, 134, 135], copolymerization [136,
137], Michael addition [138–140] or heparin-binding peptides [141]. Other
affinity-based approaches incorporated GF-binding peptides into their ma-
terials [142] or recombinantly engineered affinity domains onto growth fac-
tors [17].
To summarize, the introduction of tethered or affinity-based cytokine de-
livery approaches broadly extends the number of medical application for
biomaterials by the addition of bioactive macromolecular components, which
can interact with the cells in the tissue and therefore transmit regenerative
cues. Depending on the desired release profile and intended spatial-temporal
presentation of signaling proteins, different strategies can be utilized to load
and release signaling molecules into a biomaterial.
In addition, to the importance of growth factor binding and presentation,
the tissue ECM plays an essential role in the attraction of immune cells during
regenerative processes. In a similar manner as many growth factors and
chemokines such as MCP-1, IL-8 or stromal cell-derived factor 1 (SDF-1)
were experimentally demonstrated to electrostatically interact with negatively
charged GAGs [40, 79]. Consequently, the ECM is able to stabilize chemo-
kine gradients in the tissue and as a result enable a sustained long-term cell
migration into the target tissue [41]. This process is of significant importance
in the attraction of immune cells from the bloodstream into the wound,
where chemokines are tethered to the cell surface GAG of endothelial cells
and therefore do not dissipate into the constant flow of blood. As such, this
high affinity interaction might be an interesting target for the modulation of
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undesired signaling molecules, such as overexpressed inflammatory regulators
in the wound. In a similar approaches to locally decrease the concentration
of an unwanted signaling molecule, Lin, Metters, and Anseth [143] demon-
strated the use of TNF sequestering peptides incorporated into a PEG-based
hydrogel to isolate embedded cells in the body from apoptosis inducing TNF
signaling. Moreover, Cheung and Anseth [144] coupled specific antibodies
into a similar hydrogel system to neutralize Fas antigen and provide localized
immunosuppression for their scaffold.
In conclusion, the interaction between cytokines and the tissue matrix, ever
present in the body, is based on mutual relationship. While cytokines can
promote the deposition of ECM components, these macromolecules can, in
turn, enhance or diminish the activity of cytokines based on their essential
ability to bind and release signaling macromolecules. To interact with the
adjacent tissue, biomaterials need to mimic this process and therefore guide
the tissue regeneration processes in the body.
2.4.5 Scaffold degradability
The tissue in our body undergoes constant self-renewal and dynamic re-
structuring ranging from days to years [145]. To facilitate these processes, the
ECM provides a dynamic environment in the body, which can be degraded
and reorganized during cell-mediated matrix remodeling through specific
enzymes such as cysteine and serine proteases or matrix metalloproteinases
(MMPs). To mimic this functionality, peptide sequences were incorporated
as cross-linking motifs into synthetic polymers, which endogenously are not
susceptible to proteolytic degradation by nature. Based on the early work
of Nagase and Fields [146], various peptide sequences optimized for the
degradation by MMPs were introduced into synthetic PEG-based hydrogels
to allow for cell-responsive degradability [147, 148]. The biodegradability
of scaffolds was shown to be an essential feature for many critical processes
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in tissue engineering, such as endothelial cell migration through the material
or scaffold reorganization [124, 149]. Especially the degradation rate of the
material is a crucial parameter as in many applications, the hydrogel is offering
a mechanical support, which should sustain for a specific duration of time. At
the same time the materials also needs to be degradable to allow the cells in
the surrounding tissue to replace it with the endogenous ECM [150].
Altogether, many different properties are required in a biomaterial for
a successful integration in the tissue. The current challenge in regenera-
tive medicine is to enable materials to interact with their surrounding cells,
biomolecules and tissue by integrating degradability, adhesion, biomolecule-
based signaling and environmental cues into one comprehensive material.
2.4.6 StarPEG-GAG hydrogels as potential material in wound healing
As such starPEG-heparin hydrogels, initially developed to aid cell replace-
ment therapies for neurodegenerative diseases [34], might offer a viable tool
on the field of wound healing. This material is based on the two building
blocks: On the one hand, 4-arm star-shaped PEGs as a highly hydrophilic,
flexible polymer and on the other hand heparin, a glycosaminoglycan with
the highest anionic charge density occurring in a biopolymer (Fig. 10).
Both building blocks are widely applied in the medical field because of their
excellent compatibility [151, 152]. Based on the molar ratio of starPEG to
heparin (γ), the number of the overall cross-linking of the polymer network
and consequently the bulk stiffness of the material can be modulated (Fig. 6),
which allows for adjustment of the physical properties, such as stiffness, mesh
size and hydration to the application-specific requirements. Due to the
rational design concept applied during the development of this material, the
mechanical (structural) properties are effectively decoupled from the materials
biomolecular parameters. In result, the heparin concentration in the swollen
hydrogel remains constant independent of the cross-linking degree and can
therefore, act as the basis for any further biofunctionalization [35].
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Figure 10 – Schematic overview of a starPEG-heparin hydrogels. Hydrogel
can be biofuctionalized with covalent bound adhesion ligands or non-covalent
bound soluble effector molecules that electrostatically interact with heparin.
In addition, incorporation of MMP-cleavable peptide linkers allows for cell-
responsive material biodegradability.
The network formation of the hydrogel is based on the covalent cross-
linking between starPEG and heparin. This process can be realized through a
number of coupling strategies: First, the carboxyl groups on the heparin can
be activated with 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
and N-Hydroxysulfosuccinimide (S-NHS) to enable a carbodiimide coupling
with the amino-end-functionalized starPEG [34, 35]. This strategy allows
for the synthesis of hydrogel surfaces and discs, but based on its highly
reactive chemistry, does not permit the incorporation of cells or signaling
proteins during gel formation. To overcome this limitation another gel
system has been developed: the functionalization of heparin with maleimide
groups and the subsequent gel formation based on the Michael addition with
thiol-end-functionalized starPEG [36]. Both of the coupling strategies have
advantages in specific wound healing application and were therefore used
in this work depending on the individual requirements of the biomaterial
application. While the carbodiimide-based chemistry offers a simple strategy
to produce hydrogel wound dressings as films or thicker sheets, the more elab-
orate Michael addition based hydrogels can be applied as an unpolymerized
35
fundamentals
gel suspension and thus enables, due to the in situ forming process, a better
adapting of the material interface onto uneven wounds.
In both systems heparin is used as a main building block of the hydrogel net-
work, consequently allowing for the immobilization, presentation and release
of high capacities of protein-based signaling molecules similar to other GAG
in the ECM. Although ECM heparan sulfate is more commonly found in the
endogenous tissue, utilization of heparin profits from the greater availability,
smaller structural variance and generally better quality of the biopolymer due
to its clinical application. Furthermore, both GAGs demonstrate similar
cytokine binding-properties, altogether making heparin the more commonly
found choice in biomaterial design [25].
As discussed earlier, the electrostatic interaction between heparin and a
large number of growth factors, cytokines and chemokines enables the bio-
hybrid starPEG-heparin hydrogels to interact with its tissue environment.
Accordingly, the use of starPEG-heparin hydrogels as a delivery system for
growth factors (such as VEGF,FGF-2 or TGF-β) or chemokines (such as
SDF-1) has been extensively studied [36, 37, 153, 154]. Moreover, heparin,
as well as other GAGs, were described to increase the stability and bioactivity
of these proteins in the body [129]. The electrostatic interaction between
proteins and heparin is based on the overall charge and the position of the
charged residues, sterically limiting the interaction between both binding
partners (Fig. 9). To modulate the affinity of signaling proteins and therefore
the overall binding and release of the hydrogel, selectively desulfated heparin
was developed [39, 155]. Here, sulfate groups are selectively removed from
the heparin biopolymers to produce a new material with adjusted binding
affinity based on the reduced negative charge. The controlled binding affinity
allows for the highly tunable sustained delivery of beneficial growth factors
and other cytokines, while at the same time might also enable the specific
depletion of adverse pro-inflammatory cytokines.
Next to the biofunctionalization with soluble effector molecules that are
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released from the scaffold, several covalently linked modifications have been
developed for the starPEG-heparin hydrogel. Foremost, the incorporation
of adhesion ligands, such as the fibronectin-derived RGD domains, coupled
to the heparin building block enables cell adhesion and proliferation on the
material [34]. As for the non-covalent interaction, this functionalization
depends only on the heparin component of the hydrogel system and can
therefore be independently controlled from the physical properties, such as
material stiffness, which depends on the ratio (γ) between starPEG and
heparin.
Finally, enabling hydrogel degradation and consequently allowing the body
to remodel starPEG-heparin hydrogel scaffolds can be implemented in thema-
terial through the use of MMP-cleavable peptide linkers [134]. As described
earlier (Section 2.4.5), MMPs are proteolytic enzymes employed by the body
to degrade ECM proteins and thus enable the remodeling and formation of
new tissue. Therefore, utilizing short MMP-sensitive peptide sequences as a
cross-linker between the starPEG and the heparin, cell-responsive degradabil-
ity can be incorporated into the hydrogel material.
In summary, starPEG-heparin hydrogels were initially developed as artifi-
cial ECM substrates with the ability to provide cell-instructive cues to a variety
of cell types. This material platform offers a number of important features
that might be beneficial for the treatment of dermal wounds: based on the
heparin building block signaling cues can be provided to the cell environment
to modulate the inflammatory response or promote cell proliferation and re-
epithelialization. Further, the material can interact with the surrounding cells
by providing adhesion ligands for cellular growth and enabling cell-based
remodeling by using matrix MMP-cleavable peptide linkers. Together with
the high water content (>95%) and the low immunogenicity of the material,
the starPEG-heparin hydrogels might be utilized to modulate the signaling
environment in non-healing wounds as well as be beneficial for overall healing
by the provision of a protected moist healing environment.
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3.1 preparation of hydrogels
StarPEG-GAGs hydrogels we prepared and utilized as planar layers or three-
dimensional discs according to the experimental setup.
3.1.1 Functionalization of glass surfaces
Glass coverslips were pre-cleaned by sonication in ultrapure water for 30
min and subsequent sonication in 100% ethanol for another 30 min. After
the initial cleaning, the glass coverslips were incubated in a diluted hydrogen
peroxide - ammonia mixture (H2O : H2O2 : NH3 ratio 5:1:1) for 10 min
at 70°C to remove organic residue. Each washing step was followed by triple
rinsing in ultrapure water to remove any residues. The clean coverslips were
dried at 120°C for 1h and subsequently immersed in 20 mM solution of 3-
aminopropyltriethoxysilane (Sigma-Aldrich, Germany) diluted in a mixture
of 90% (v/v) isopropanol for 2 h. Afterwards the aminosilane-treated glass
coverslips were dried at 120°C for 1 h. Thereafter the glass coverslips were
spin coated with 0.3% (w/v) poly(ethylene-alt-maleic anhydride) (PEMA)
in a mixture of acetone and tetrahydrofurane (1:2; Fluka, Germany). After
annealing at 120°C for 2 h, the glass coverslips were washed four times in
acetone to remove excess polymer. Polymer-coated coverslips were further
autoclaved and reheated to 120°C for 2 h before storage at room temperature
in a dry environment. To ensure cyclization of the anhydride ring, the PEMA
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coated coverslips were incubated at 120°C for 1 h before the application of
the hydrogel solution.
3.1.2 Hydrogel formation with EDC - NHS chemistry
Hydrogels were prepared from Heparin (MW=14,000) (Merck, Germany)
activated with a mixture of EDC and S-NHS (both Sigma–Aldrich, Ger-
many) at a 2:1 ratio combined with amine end-functionalized 4-arm starPEG
(MW=10,000) (JenKemTechnology, China). Therefore, all components were
dissolved in ultrapure water on ice. Heparin was mixed with the EDC/S-NHS
solution and kept on ice for 15 min to activate the heparin carboxyl groups. A
2-fold molar excess of EDC to amine groups of PEG was used. Subsequently,
the amine end-functionalized 4-arm starPEG was added to the activated
heparin. To modulate the material stiffness, the molar ratio of starPEG to
heparin (γ) was varied from 1.5 to 6. The pre-polymerized gel mix was then
cast into flat planar surfaces applying the gel mixture onto a PEMA coated
coverslip and adding a hydrophobic coverslip to flatten the gel. Alternatively,
free standing hydrogel discs were formed between two hydrophobic coverslips.
After 14 h at room temperature the polymerization reaction was finished and
the hydrophobic coverslips were removed. The formed hydrogels were washed
at least five times with phosphate buffered saline (PBS) and sterilized by UV
treatment for 30 min. For further functionalization with adhesion peptides,
the swollen hydrogels were washed with 0.67 M phosphate buffer (pH 5.0,
Merck, Germany) at 4°C. To reactivate the carboxyl groups the hydrogels were
then treated with a solution of 50 mM EDC and 25 mM S-NHS in 0.67 M
phosphate buffer, 4°C for 45 min. After the activation the hydrogels were
washed in 0.1 M borate buffer (pH 8.0, Merck, Germany) and immediately
immersed in 50mg/mlNH2 –RGD–SP peptide dissolved in borate buffer for
2 h (Tab. 2). To remove unbound peptide from the materials the hydrogels
were subsequently excessively washed with PBS.
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3.1.3 Hydrogel formation with thiol - maleimide chemistry
For the formation of in situ forming hydrogels heparin was functionalized
with maleimide groups in molar ratio of 1:6. The pre-functionalized was then
mixed with thiol end-functionalized 4-arm starPEG (MW=10,000) (JenKem
Technology, China) to form hydrogels. Biofunctionalization with adhesion
peptides could be achieved by directly mixing cysteine-containing RGD pep-
tides in the pre-polymerized gel mixture (Tab. 2). The molar ratio of starPEG
to heparin was varied from 0.75 to 1.5.
Name Sequence M [g/mol]
RGD for EDC-NHS chemistry NH2-GWGGRGDSP-CONH2 890
RGD for thiol - maleimide chemistry NH2-GCWGGRGDSP-CONH2 990
Table 2 – Sequences of adhesion peptides used for biofunctionalization of
hydrogels.
3.1.4 Rheometric measurement of hydrogel discs
Storage moduli of the hydrogel materials were determined by rotational
rheometry. For this mechanical properties of hydrogel discs were measured
with a 25 mm parallel plate geometry in an Ares LN2 (TA Instruments,
Germany). The frequency sweeps were carried out at a shear frequency range
from 10−1 rad s−1 to 102 rad s−1 with a strain amplitude of 2%.
3.1.5 Characterization of cytokine uptake and release
Cytokine release and uptake experiments were performed either on hydrogel
samples as surface bound planar layers in custom-made incubation chambers
or with three-dimensional hydrogel droplets in a protein low binding reaction
tube (Sarstedt, Germany). Both experimental setups allow for low unspecific
interactions with the surface of the container. For immobilization of the
analyte to the material, the cytokine was either incubated for 24 h at room
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temperature with the hydrogel material or directly mixed in the gel mixture
before polymerization. Following the loading procedure, hydrogels were twice
with 0.4 ml release medium containing Dulbecco’s modified eagle medium
(DMEM) medium supplemented with 0.1% (v/v) Proclin 300 and 0.1%
(w/v) bovine serum albumin (BSA) (Sigma-Aldrich, Germany). Hydrogels
were incubated at 37°C immersed in 0.4 ml release medium. After the
indicated time periods the medium was removed from the hydrogel and
immediately frozen at -80°C for later quantification. To replace the old
medium, 0.4 ml fresh release medium were used. If hydrogel degradation
was desired, the release medium was additionally supplemented with 0.1
U/ml Collagenase IV (Biochrom, Germany). To conclude the cytokine
release experiment, all samples were thawed and analyzed for the protein
concentration by enzyme-linked immunosorbent assay (ELISA).
3.2 culture of human & murine cells
3.2.1 Isolation and differentiation of murine dermal fibroblasts
Murine dermal fibroblasts were derived from the back skin of eight weeks
old, male C57BL/6JOlaHsd inbred mice (envigo, Netherlands). For this a
2cm² piece of back skin was removed and shredded into small pieces. The tis-
sue fragments were further homogenized by digestionwith 0.5mg/ml Liberase
DH (Roche Diagnostics, Germany) in DMEM (PAN biotech, Germany)
medium for 1h at 37°C. After tissue homogenization, the enzyme reaction
was stopped by adding fetal calf serum (FCS) to a total concentration of 10%
(v/v) (Biochrom, Germany). The resulting cells were filtered through a 70 µm
cell strainer to remove debris and cultured on tissue culture plastic in DMEM
(PAN biotech, Germany) medium with 10% (v/v) FCS.
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3.2.2 Isolation & differentiation of murine macrophages
Murine macrophages were derived from bone marrow of eight week old,
male C57BL/6JOlaHsd inbred mice (envigo, Netherlands). For this the
bone marrow was isolated from the tibia and femur and flushed out with
pre-warmed Iscove’s Modified Dulbecco’s Medium (IMDM) medium with
10% Pannexin BMM (PAN biotech, Germany). Tissue isolation was per-
formed in accordance with institutional and state guidelines and approved
by the Committee on Animal Welfare of Saxony. Cells were dissociated
from the bone marrow by rigorous pipetting and straining through a 70
µm filter. The resulting cell mixture was the differentiated in untreated
plastic flasks for seven days with 15 ng/ml macrophage colony-stimulating
factor (M-CSF) (Peprotech, Germany). The differentiation of the cells was
validated by staining for the murine macrophage surface marker F4/80 and
CD11b (BDBiosciences, Germany), resulting in a > 97% pure culture of pure
macrophages. Differentiated macrophages were seeded and cultured for 24
hours before experimental treatment. After priming the cells with 10 ng/ml
IFN γ (Peprotech, Germany) the cells were challenged with 10 ng/ml LPS
(Sigma-Aldrich, Germany).
3.2.3 Culture of human & murine cell lines
All cell lines were acquired fromAmericanTypeCulture Collection (ATCC)
and cultured under the conditions indicated in (Tab. 3, Page 44) at 37°C and
100% humidity. For all cell lines the medium was changed every two to three
days.
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3.3 in vitro methods
3.3.1 Enzyme-linked immunosorbent assay (ELISA)
For the analysis of protein concentrations by ELISA, 96-well plates with
high protein binding capacity (Microlon 600, Greiner, Germany) were incu-
bated with an analyte specific capturing antibody in PBS for 24 h at room 4°C
(RnD Systems, USA or ebioscience, Germany). After the immobilization of
the antibody, plates were washed with PBS with 0.1% (v/v) Tween 2 )Sigma-
Aldrich, Germany) and blocked with 1% (v/v) BSA or 10% FCS in PBS for
at least 1 h. If needed, plates were stored in blocking solution supplemented
with 0.1% (v/v) Proclin 300 for several month. For the detection procedure,
the blocking solution was removed from the plate and the sample solution was
incubated together with a corresponding standard on the plate for 2 h. After
the first incubation, the plate was washed with 0.1% Tween-20 in PBS several
times and a biotinylated detection antibody was added. After a second 2h
incubation the plate was washed repeatedly and incubated with a streptavidin-
horseradish peroxidase (HRP) conjugate. Following a 20 min incubation the
plate was washed again several times and the tetramethylbenzidine (TMB)
substrate solution (ebioscience, Germany) was added to the antibody analyte
sandwich construct. After 10 min of development time, the color reaction
was stopped by adding 1 N sulphuric acid and the absorbance was measured
on a Sunrise plate reader (Tecan, Austria). The analyte concentrations were
determined by fitting a four parameter logistic regression model onto the
standard curve.
3.3.2 Bead-based multiplex immunoassay
In addition to the ELISA method bead-based multiplex assays have been
used to determine the amount of secreted cytokines in solution. For this cell
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culture supernatant from macrophages was immediately frozen at -80°C after
the sample collection. To determine the concentration of multiple cytokines
in themedium ProcartaPlexMultiplex Immunoassays (ebioscience, Germany)
were utilized. In brief, the sample solutions were incubated with capture
antibodies against specific analytes coupled to magnetic polystyrene beads.
After a 2 h incubation, the unbound proteins were separated from the beads
by magnetic separation and subsequent washing with 0.1% Tween-20 in PBS.
Thereafter the biotinylated detection antibody was incubated with the beads,
followed by another 1h incubation period and magnetic separation. After
the coupling of a streptavidin-polyethylene (PE) conjugate to the detection
antibody, the amount of bound analyte was detected using a Bioplex 200
(Biorad, USA). The analyte concentrations were determined by fitting a four
parameter logistic regression model onto the standard curve.
3.3.3 Live/Dead Staining
Living cells were stained in with 4mM Calcein-AM (Merck, Germany)
and 1.5 mM propidium iodide (PI)(Sigma-Aldrich, Germany) in PBS for 15
min at 37°C. As a control cells were treated with 10% saponin (PromoKine,
Germany) to generate dead cells. The stained cells were imaged using an
Axio Observer (Zeiss, Germany) or for confocal microscopy a Sp5 (Leica,
Germany).
3.3.4 Crystal violet staining
Cells were first fixated with 4% paraformaldehyde (PFA) (Sigma-Aldrich,
Germany) for 10 min at room temperature. Subsequently, the fixed cells were
washed twice with PBS and stained with 0.25%m/v crystal violet in ultrapure
water for 30 min. After extensive washing with ultrapure water, the cells were
imaged using an Axio Observer (Zeiss, Germany).
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3.3.5 Cell proliferation assay
Cell proliferation assays were used to determine cytokine bioactivity. Thus,
the cytokines were incubated with cell lines sensitive for this specific cytokine
for up to 96 h depending on cell growth rate and sensitivity. Change
in proliferation was determined using Prestoblue viability reagent (Thermo
Scientific, Germany) measured on a Genious plate reader (Tecan, Austria).
3.3.6 RNA extraction & analysis
Total RNA was isolated from macrophages using Direct-zol RNA Kits
(Zymo, USA). In short, medium was removed from cells and TRI reagent
containing phenol and guanidine thiocyanate was added to lyse the cells. After
15 min incubation mixture was vigorously mixed and supplemented with a
part pure ethanol (Sigma-Aldrich, Germany). To separate the RNA from the
solution, the mix was filtered through a silica column via vacuum suction. The
column was washed according to the manufacturer’s instructions. Thereafter
the RNA was eluted in ultrapure water and immediately stored at -80°C.
To determine the quantity and quality of the extracted RNA, samples were
analyzed using a Nanodrop 1000 (Thermo Scientific, Germany). In addition
200 ng sample were visualized in a 2% agarose gel electrophoresis, which
was imaged with GelRED (Biotium, USA) on a myECL imager (Thermo
Scientific, Germany).
3.3.7 cDNA synthesis
To synthesize cDNA for subsequent analysis, 1 µg RNA was converted
using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo
Scientific, Germany). Previous of the synthesis reaction, residual genomic
DNA was digested from the RNA with DNase I kits (Zymo, USA). After
each step the quality of the synthesis product was determined by real time
rt-PCR.
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3.3.8 Quantitative real time rt-PCR
To quantify gene expression, cDNA was measured using the DyNAmo
ColorFlash SYBR Green qPCR kit (Thermo Scientific, Germany). Primer
sequences were designed using Primerblast (Tab. 4,Page 49).
3.4 statistical analysis
All experimental data was analyzed using Prism (GraphPad, USA). Primar-
ily analysis of variance (ANOVA) with Turkey post-hoc test was used on the
results. Levels of significance were set as *=p <0.05, **=p<0.01, ***=p<0.001.
3.5 software use
For the molecular visualization the open-source version of PyMOL Molec-
ular Graphics System (Schrödinger, LLC, Mannheim) was used. Protein hep-
arin docking analysis were computed using Cluspro 2.0 [156–159]. Macro-
molecular electrostatics calculation we computed using APBS [160] with
PDB2PQR [161, 162]. All illustrations were realized using Adobe Illustrator
and Adobe Photoshop. Image data from microscopy or western blot analysis
were processed using Fiji.
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4
SCAVENGING INFLAMMATORY CHEMOKINES TO
CONTROL IMMUNE CELL INFLUX IN THE
WOUND
The following chapter contains experimental results from the collaboration projects
with Nadine Lohmann (University Leipzig, Department of Dermatology, Venerol-
ogy and Allergology). These datasets were previously presented during the World
Biomaterial Conference 2016 in Montreal [163] and are currently prepared for
publication. For more information, please refer to the original publication. Please
refer to Chapter 8 for supplementary experimental methods of the experiments
conducted by our collaboration partners and to Chapter 9 for the full list of
contributions from the authors.
Chemokines are a class of signaling molecules, which selectively recruit and
activate cells during inflammation [164]. As a result, they are involved in
the development of a broad range of inflammatory diseases such as multiple
sclerosis, rheumatic arthritis or chronic wounds [165]. During the wound
healing process, chemokines are released by damaged endothelial cells, fi-
broblast and platelets at the site of injury and establish a chemoattractant
gradient to promote immune cell invasion, which is essential for the initial
inflammatory phase of acute wound healing. However, when overexpressed
in the wound, chemokines can cause an uncontrolled influx of immune cells,
which drives further production of inflammatory mediators, including even
more chemokines, eventually leading to a prolonged inflammation and finally
to the development of a chronic wound [166–168].
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One essential feature of their chemoattractant function in the body is
the ability of chemokines to bind to extracellular matrix GAGs, such as
heparan sulfate or heparin [40, 169]. More in detail, due to the electrostatic
interactions of positively charged amino acid residues of the chemokines
and negatively charged GAG sulfate groups multiple binding, release and
rebinding events occur. Therefore, the interplay of GAG concentration /
sulfation degree and chemokine concentration modulates the transport pro-
cesses, i.e. the generation of long ranging chemokine gradients that efficiently
control activation and migration of immune cells [41, 42]. Beyond, the
binding to glycosaminoglycans protects the chemokines against proteolytic
inactivation [169–171], mediates oligomerization of the chemokines, which
is an essential step for receptor activation [40, 172] and accumulates the
chemokines near the cell surface that further influences their activity [173].
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Figure 11 – Schematic view of modulatory starPEG-heparin hydrogels control-
ling chemokine gradients. Inflammatory wound releases chemokines to attract
immune cells. These immune cells secrete more chemokines in turn attracting
more cells. Hydrogel breaks up this loop by binding and neutralizing the
excessive amounts of chemokine and helps the inflammation to resolve.
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In this chapter, heparin-based hydrogels were developed to reprogram
these pro-inflammatory chemokine gradients by utilizing the strong affinity
between the chemoattractant proteins and heparin to scavenge and inactivate
these molecules [172]. The hydrogels are designed to display an unmatched
high density of chemokine binding sites within a sterically easily accessible
hydrogel network and thus - if utilized as wound dressing - form an efficient
local sink for such pro-inflammatory molecules. In consequence, massive
amounts of chemokines are scavenged with a high affinity within the hydrogel
and are therefore depleted from the local source (the inflammatory wound)
stopping the recruitment of further immune cells and resolving the inflamma-
tory process (Fig. 11).
The interaction of chemokines and heparin depends on the overall negative
charge and the position of the sulfate groups at the GAG [131, 174] (Fig. 11).
In consequence, selectively desulfated heparin derivatives were utilized to form
modular hydrogels in order to control chemokine scavenging and inactivation
and thus, gradient formation paving the way for an efficient modulation of
the anti-inflammatory properties of hydrogel based wound dressings.
4.1 results
4.1.1 Engineering heparin-based hydrogels to scavenge chemokines
Within this study, a previously established modular hydrogel material based
on star-shaped poly(ethylene glycol) (starPEG) and heparin was investigated
as an adaptable material to modulate the inflammatory environment and
support wound healing [155, 175]. To engineer heparin-based hydrogels
for chemokine scavenging, first the polymer network properties have to be
optimized. Therefore, hydrogels compliant to dermal skin with a storage
modulus of ≈ 2.5 kPa (≈ E-modulus of 7.5 kPa assuming a Poisson ratio of
0.5, (Fig. 12, A)in good agreement with a Young’s moduli between 4.5 and 8
kPa of human skin [175], and display a reasonably high mesh size significantly
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larger than the chemokines to be scavenged (radius of gyration (Rg) of wound
relevant chemokines MCP-1 and IL-8 < 2 nm, mesh size of the hydrogel
>10 nm (Fig. 12, B) were synthesized. The hydrogels were tuned to display
similar physical properties utilizing inert star-PEG and heparin with variable
sulfation pattern as building blocks where the interaction with the chemokines
are meant to be correlated to the net charge and charge distribution of the
chemokines rather than to any unwanted sterically effects (Fig. 12, A and
IEP>9, equilibrium dissociation constant (KD) to heparin 1-2 µm for MCP-1
and IL8, (Fig. 12, B). Accordingly, to modulate the binding of the chemo-
kines affinity mediating sulfate groups [131, 174] were selectively removed
from the heparin to obtain hydrogels with adjustable mechanical properties
but variable sulfation degree [155] of approx. three sulfate groups (PEG/SH),
approx. two sulfate groups PEG/N-dSH and one sulfate group (PEG/6O-
NdSH) per disaccharide unit (Fig. 12, A - PEG/SH: 100%, PEG/N-dSH:
68%, PEG/6ON-dSH: 33.7%). Furthermore, as solely sterically interacting
and non-affine control PEG hydrogels with similar stiffness and mesh size
were synthesized. Next, the binding capability of the different hydrogels
for chemokines involved in the attraction of immune cells in the wound
was investigated. More in detail, the binding of wound healing prominent
chemokines MCP-1 and IL-8 [166, 168] to the hydrogel scaffolds have been
systematically investigated (Fig. 12).
The binding kinetics for the four hydrogel sets were determined by incu-
bation of preformed scaffolds with either 100 ng of MCP-1 or IL-8 over
24h (Fig. 12, C/D). Subsequently, nearly all of the chemokines were scav-
enged by different heparin-based hydrogels independent of their sulfation
degree. After only three hours already 50% of the total chemokine concen-
trations was sequestered by the hydrogels formed of the different heparin
derivatives. In contrast, only 20% of the chemokines were bound to the
PEG/PEG control gels with no further increase after the first 3h of incubation.
The strong interaction with the heparin-based hydrogel is in line with previous
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Figure 12 – Physical properties and chemokine scavenging characteristics of
starPEG-heparin gels. (A) Storage modulus, mesh size, and sulfate content were
characterized for the different hydrogels (PEG/PEG, PEG/SH, PEG/N-dSH,
PEG/6ON-dSH). n = 3. (B) Biochemical properties of MCP-1 and IL-8. (C)
Binding kinetic and overall capacity of starPEG-heparin hydrogels for MCP-1.
(D) Binding kinetic and overall capacity of starPEG-heparin hydrogels for IL-8.
Binding for both was characterized in DMEM supplemented with 2%FCS and
Proclin 300 was analyzed by ELISA over 168 h. n = 6. Binding saturation was
calculated based on the estimation of chemokine one binding site per heparin
molecule.
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results, which determined the KD of MCP-1 and IL-8 in the lower µM
range (Fig. 12, B) [176–183].
Moreover, the binding capacity for chemokines of the different materials
was determined by incubation with increasing concentrations of MCP-1 or
IL-8. A linear correlation between the amount of applied cytokine and the
bound cytokine was found for all heparin derivatives. While almost 100% of
the applied MCP-1 was bound to the hydrogels (Fig. 12, C/D), only 70% of
the applied IL-8 was bound after 24h of incubation (Fig. 12, C/D). As for the
impact of the desulfation, the removal of the 6O-sulfate group in particular
impacted the binding affinity ofMCP-1, while the desulfation of theN-sulfate
did alter overall sequestration. In contrast, for the IL-8 not a specific sulfate
position on the heparin, but the overall sulfate content affected the bound
amount. Even though differences in overall affinity were detected, no satura-
tion of the scaffolds could be determined in the assessed concentration range
for either of the tested chemokines. Based on the conservative assumption of
one binding site per heparin molecule, we calculated that even a magnitude
higher 30 µg chemokine/µl hydrogel might be bound for the fully sulfated
PEG/SH hydrogels.
56
4.1 results
4.1.2 Heparin-based hydrogels reduce migration of immune cells
To assess the ability of the biohybrid hydrogels to control inflammation
in a relevant context, preformed scaffolds were incubated with conditioned
medium from inflammatory activated macrophages or dermal fibroblasts.
This mix of inflammatory cytokines and chemokines resembles the signaling
environment found in the wound bed during the inflammatory phase [43,
184]. After the incubation of the inflammatory medium with the hydrogel
scaffold for 24 h, the remaining concentrations of various inflammatory
markers were determined by ELISA.
Our data demonstrate that the cytokine sequestration by the heparin-based
hydrogels was solely directed towards the two tested chemokines MCP-1 and
IL-8 (Fig. 13, A), while other pro-inflammatory cytokines as TNF, IL-1β
and Interleukin 6 (IL-6) were unaffected (data not shown). Furthermore,
differences were observed in the capacity ofMCP-1 and IL-8 sequestration for
the hydrogels formed of different heparin derivatives. While scaffolds based
on fully sulfated heparin (PEG/SH) scavenged about 80% for both tested
chemokines, the scaffolds based on N-dSH depleted only 60% of MCP-1
and IL-8. Moreover, the hydrogels based on 6O-N-desulfated heparin scav-
enged even less chemokine (MCP-1: 30% and IL-8 50%). The decrease in
chemokine scavenging capability correlated with the overall reduced sulfation
for both chemokines (Fig. 13, A).
As MCP-1 and IL-8 both belong to the chemokine family, their ma-
jor function is the selective recruitment of immune cells to sites of inflam-
mation, with MCP-1 and IL-8 predominantly attracting monocytes and
polymorphonuclear netrophils (PMNs), respectively [185, 186]. The im-
pact of MCP-1 and IL-8 sequestration on their chemoattractant function
was investigated in transmigration assays with primary human monocytes or
PMNs. Therefore, conditioned medium from activated dermal fibroblasts, as
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described above, was used as chemoattractant stimuli to promote migration
of monocytes and PMNs. The transmigration of monocytes and PMNs
was significantly reduced after incubation of the medium with PEG/SH
or PEG/N-dSH hydrogels (Fig. 13, B). In comparison, no effect of the
PEG/PEG hydrogels in their chemoattractant activity of the conditioned me-
dium was detected. For PEG/6ON-dSH hydrogels, only a marginal decrease
in migration was observed, which is in line with its low capacity for MCP-1
and IL-8 sequestration. Thus, the heparin-based hydrogels, depending on
their particular sulfate content, were able to diminish the chemoattractant
activity of the inflammatory conditioned medium.
However, while our data propose that the hydrogel scaffolds affect mi-
gration through their sequestration of MCP-1 and IL-8, other chemotactic
factors influencing monocytes and PMNs [187] might also be present in
conditioned medium from activated dermal fibroblasts and therefore con-
tribute to the migration. Even though, transmigration assays with either
MCP-1 or IL-8 alone revealed a similar correlation of chemokine sequestra-
tion and reduced immune cell migration as for the inflammatory medium
(data not shown). This implies that heparin-based hydrogels attenuate the
chemoattractant activity mainly through the chemokine binding capacity of
the incorporated GAGs.
4.1.3 Heparin-based hydrogels decrease wound immune cell influx and
inflammatory signaling
The murine model of full-thickness excisional wounds was used to test
chemokine sequestration of the heparin-based hydrogels in a complex in-
flammatory process in vivo in 12 weeks old C57BL/6 mice. Therefore,
preformed scaffolds of PEG/SH and PEG/N-dSH, the two materials with
the highest effect on immune cell migration, were applied onto wounds
directly after their infliction. The implanted material caused no adverse
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Figure 13 – Effects of starPEG-heparin hydrogel scavenging on migration of
monocytes and PMNs. Inflammatory conditioned medium was incubated
with hydrogels for 24h at 37 °C. (A) Levels of the remaining mediators were
determined by ELISA. n = 4. (B) Remaining chemoatractant activity was
determined in a transwell migration assay with human monocytes and human
PMNs .n = 4. Data contributed by Lohmann et al. [163].
reactions, such as increased inflammation of the wounds over the course of
the experiment (Fig. 14, A).
Five days post wounding hydrogels were recovered from the wounds and
analyzed for sequestered chemokines from the wound area. Thus, MCP-1
levels in the hydrogel were determined after previous mechanical disintegra-
tion of the hydrogel scaffolds. High amounts of MCP-1 were recovered from
PEG/SH and PEG/N-dSHhydrogels whereas no recovery ofMCP-1 from the
PEG/PEG hydrogels was detected (Fig. 14, B). IL-8 could not be assessed,
since no homologue of IL-8 in mice is known to date [188].
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A Hydrogel after 5  days of implantation
C Immune cell invasion in wound tissue 5 days after implantation
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Figure 14 – Effects of starPEG-heparin hydrogel scavenging in full thickness
excisional wounds. 6 mm wounds were inflicted in C57BL/6 mice and treated
with hydrogel discs for five days. Wounds and hydrogels recovered from four
different animals were analyzed. (A) Representative gross anatomy of hydrogel
disc in wounds after 5 days. (B) MCP-1 concentration scavenged in hydrogel
was determined by ELISA. (C) Immune cell infiltration of PMNs and macro-
phages was analyzed from digested wounds by cytometry. Data contributed by
Lohmann et al. [163].
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To further investigate the impact of chemokine sequestration by the heparin-
based hydrogels on the immune cell influx, wounds were assessed for in-
filtrated monocytes and PMN. Significantly high amounts of infiltrating
PMNs and monocytes were found in wounds treated with PEG/PEG control
hydrogels compared to the unwounded skin (Fig. 14, C). In contrast, in
wounds treated with PEG/SH or PEG/N-dSH hydrogels significantly lower
the amounts of PMNs and monocytes were detected (Fig. 14, C).
With the GAG-based hydrogels sequestering large amounts of chemokines,
it might be possible that the bound chemokine in the scaffoldmight attract im-
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Figure 15 – Effects of starPEG-heparin hydrogel scavenging in full thickness
excisional wounds. 6 mm wounds were inflicted in C57BL/6 mice and treated
with hydrogel discs for five days. Wounds recovered from ten different animals
were analyzed. (A) Gene expression of inflammatory cytokines in wound tissue.
Each symbol represents one wound. Data contributed by Lohmann et al. [163].
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mune cells to the implant. However, immunofluorescence analysis of wound
sections revealed no accumulation of CD11b+ immune cells at the surface
or within the network of PEG/SH hydrogels (data not shown). Moreover,
a decreased gene expression of inflammatory signaling factors was detected
in wounds treated with PEG/SH or PEG/N-dSH hydrogels compared to
wounds treated with the PEG/PEG controls. Therefore, the expression of
TNF, IL-1β or MCP-1 remained comparable to the expression measured in
unwounded skin samples (Fig. 15).
To summarize, whenwounds were treated with hydrogels containingGAGs,
the overall immune cell influx as well as the expression of inflammatory
signaling factors in the wound was decreased to levels of unscathed skin,
therefore reducing the overall inflammatory environment in the wound.
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4.2 discussion
Overexpression of inflammatory chemokines, such as MCP-1 and IL-8,
causes a prolonged, persistent inflammation and therefore impairs the wound
healing process. Consequently, this class of signal proteins is an attractive
target for the development of novel strategies to control inflammation [169].
Current therapeutic approaches mainly focus on the promotion of tissue pro-
liferation, rather than addressing the underlying imbalance of inflammatory
cues in the chronic wound [2, 3, 17, 19]. In contrast, the modulation of
chemokine gradients in the wound utilizing heparin-based hydrogels offers a
new concept to control the inflammation and might consequently facilitate
the development of novel therapies for the treatment of chronic wounds.
In this study, we developed a translational approach for inflammation-
resolving wound dressing materials based on the high-affinity interaction
between chemokines and GAG. It has been previously shown that GAGs,
such as heparin, are able to interact with varying chemokines [40, 79] involved
in wound healing including MCP-1 [181–183] and IL-8 [176–179]. This
strong interaction of chemokines and GAGs is largely based on a GAG-
binding consensus sequence found in nearly all chemokines [131, 181] and
has been shown to modulate the overall bioactivity of the chemokines [180].
Based on this phenomenon we developed a set of starPEG-GAG hydrogels
and characterized their effects on migration of immune cells, inflammation
and overall wound healing.
As discussed earlier, previous tissue engineering approaches utilized the
mitogenic effects of growth factors to improve healing results [17, 19, 63].
Although the delivery of growth factors can be used to improve wound healing,
most often supraphysiological high doses have to be used to achieve the desired
effect [17, 19, 63]. The strongly proteolytic environment found in chronic
wounds rapidly degrades applied protein-based therapeutics and therefore
63
scavenging inflammatory chemokines
decreases their drug efficacy. In addition, the right dosage to generate the
desired effect is hard to control: while too low concentrations are not sufficient
to provoke a cellular response, too high doses can have severe side effects.
For example recombinant human VEGF (telbermin) – a promising growth
factor beneficial in the promotion of dermal wound healing [39] – and
currently tested for the treatment of diabetic foot ulcers [189], may lead to
the pronounced neovascularization in non-target tissue or the promotion of
tumor growth [18, 123]. Moreover, FGF-2, another recombinant growth
factor marketed as Trafermin for the treatment of diabetic ulcers induced
the formation of excessive granulation tissue in a number of patients [190].
Although the promotion of tissue proliferation is a valid option for treatment,
it does not tackle the underlying problem of persistent inflammation. In
contrast, we could prove that starPEG-GAG hydrogels were able to promote
wound healing without delivering any bioactives, through the controlled
modulation of chemokine gradients. Instead of promoting growth in an
uncontrolled manner, we rather facilitate the physiological transition from
inflammation to proliferation by the attenuation of immune cells and inflam-
matory signal molecules of the wound environment and thus let the body
control the wound healing process by itself.
When applied onto excisional wounds, the starPEG-GAG hydrogels reduce
immune cell invasion and inflammatory signaling in the wound tissue. This
effective down-regulation of inflammation in the wound results from the high-
affinity scavenging of chemokines by the GAG component in the hydrogel.
Although other inflammatory mediators such as TNF, IL-1β or IL-6 might
also interact with the starPEG-GAG hydrogels and therefore be involved in
the regulatory mechanisms, we could not detect their depletion in our test
setup. Based on the known strong chemokine affinity of GAGs and char-
acterization of the binding profiles of our starPEG-GAG hydrogels, we can
conclude that the anti-inflammatory effect of the GAG-based hydrogels relies
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mainly on the scavenging of chemokines. Thus, when applied on top of the
wound, the hydrogel network interacts with the wound bed and acts as a local
sink for chemokines. In the hydrogel scaffold, the strong affinity allows for
a sufficient sequestration of chemokines to neutralize their chemoattractant
function and consequently prevent the influx of immune cells into the wound.
As a secondary effect of the reduced number of immune cells in the wound,
the overall expression of inflammatory cytokines such as TNF or IL-1β is
also diminished. The so engineered wound environment benefits from the
decreased inflammatory signaling and in consequence promotes soft tissue
growth. Even in wounds with inertly high inflammation as for example in
animals suffering from diabetes mellitus the anti-inflammatory influence of
the GAG-based hydrogels is sufficient to enhance wound healing and full
wound closure under these impaired healing conditions within only 10 days.
Heparin has long been recognized for its anti-inflammatory properties [174].
Thus, reduced infiltration of immune cells to inflamed sites after administra-
tion of soluble heparin was demonstrated in various in vivo models of acute
inflammation [191, 192]. A number of different mechanisms of the anti-
inflammatory action of heparin has been proposed, which include expression
of endothelial adhesion molecules important for leukocyte adhesion and
transmigration or the expression of many other inflammatory genes [192–
194]. Importantly, in all models heparin was applied as a soluble molecule. In
our study heparin was stably conjugated to the hydrogels which excludes anti-
inflammatory effects based on its internalization. Therefore, the electrostatic
conjugation of inflammatory chemokines to the heparin inside the hydrogel
network seems to be the principal mechanism that effectively neutralizes
chemokine signaling and consequently enables the anti-inflammatory effects
of the hydrogel.
In addition, the underlying rational design concept of the starPEG-heparin
hydrogels allows for the modulation of mechanical properties at constant
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heparin concentration. We could therefore optimize the material to exhibit
a good mechanical compatibility with the human skin, but in parallel no
interference with sterical effects on the diffusion rate for the chemokines are
expected.
Through the integration of heparin as a main building block of the hy-
drogel network, an unmatched high capacity for chemokine binding could
be achieved. This allows the hydrogel to act as an inflammatory sink for an
extended period of time, while simultaneously providing a moist environment
promoting wound healing. Furthermore, capitalizing on the high seques-
tering capability and given the fact that heparin binds a plethora of signal
molecules [129] the material may become beneficial beyond the hereby tested
application as inflammation resolving wound-dressing for the development
of novel strategies to control cell migration associated processes in various
diseases. In addition, the selective desulfation of the heparin enabled the
controlled modulation of the scavenging effect of the hydrogels. While this
effect has been shown to support the controlled delivery of growth factors [39],
we could extend its application for the fine-tuning of chemokine scavenging.
In future therapeutic applications, the inflammation would not have to be
totally diminished but could also just be partially reduced to allow for a less
severe intervention.
In here we present the sequestration of chemokines via a GAG-based hydro-
gel scaffold as a tool to modulate inflammation in the wound environment
and promote the healing of dermal wounds in diabetic animals utilizing skin
relevant compliant hydrogels. In conclusion, we suggest the modular heparin-
based hydrogel system as a versatile toolbox for efficient chemokine scavenging
for the application for chronic wounds in humans might be more efficient
than current inert wound dressings materials.
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5
PROMOTION OF REGENERAT IVE MACROPHAGE
POLAR IZAT ION IN INFLAMMATORY
ENVIRONMENTS
Macrophages play a central role in the coordination of the body’s repair
response as they are able to provide a wide range of functionalities essential
during the wound healing process. Their behavior is based on the ability
to probe the wound for cellular and non-cellular signal molecules, such as
cytokines, apoptotic cells or invading pathogens, and integrate these signal-
ing cues into their cellular response. Depending on the environment, the
macrophages reaction and functional role can be quite versatile: from their
microbiocidal abilities, which protects the host from infections, but may also
cause collateral damage to the adjacent tissue; to their regenerative actions,
in which they release growth factors and support the deposition of newly
synthesized matrix. To allow this wide spectrum of activities, macrophages
have developed different sets of polarization states, which enable them to
undergo dramatic behavior changes to provide the functionality needed at
a particular point during wound healing. According to their surrounding
signaling milieu they are able to switch between these polarizations and
consequently adjust their functionality. Most prominently this responsive
behavior is demonstrated during the acute wound healing process, where
macrophages are involved in the transition between the inflammatory and
the proliferative phase. While in the early healing stage inflammatory (M1)
macrophages are most prominent in the wound, the balance shift in the
later proliferative phase, where regenerative (M2a) and immunomodulatory
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macrophages (M2c)are more commonly found [59, 195, 196]. Thus, mac-
rophages act as a ”jack of all trades” in the wound healing process able to
integrate different environmental requirements and orchestrate the progress
of the body’s repair cycle accordingly.
As described in Section 2.2 the inflammatory reaction found in chronic
wounds is highly excessive and persists for a prolonged time period. While
the underlying origin of the continuous inflammation can be diverse, the
resulting pathogenic state is commonly represented in the dysregulation of
inter-cellular signaling molecules, resulting in the massive overexpression of
inflammatory mediators, such as TNF, IL-1β, and chemokines. While these
signal molecules are also produced by the immune cells during the early phase
of the acute wound healing process, their presence later diminishes, allowing
the inflammation to resolve. Besides the aberrant inflammatory cues, the
expression of growth factors, such as VEGF, TGF-β or IGF1, is drastically
reduced in chronic wounds, impairing tissue formation even further. Based
on this imbalance between inflammatory and mitogenic signaling cues and
the resulting prolonged activation of inflammatory cells, the transition from
inflammation to proliferation does not take place in chronic wounds and
consequently does not permit for wound closure.
In several previous studies macrophages have been demonstrated to be in-
volved in the inflammatory balance and thus themanagement of the transition
from inflammation to proliferation in wounds [195, 197, 198]. In addition,
the treatment ofmurine woundwith IL-4 or IL-10, the two factors that induce
regenerative (M2a) and regulatory (M2c) macrophages respectively, have both
been beneficial for wound closure and quality of the newly formed tissue [199–
202]. Although the therapeutical application of these two signaling proteins
would be of interest to enhance wound healing, their translation into the
clinic was not yet successful. As for most cytokines, a major drawback in
IL-4 or IL-10 as a therapeutic agent is their short serum half-life and low
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bioavailability in the body [203]. The ubiquitous levels of proteases found in
nearly all tissues degrade the cytokines, thus decrease the overall half-life of
the proteins dramatically and enhances their elimination from the body [122,
204, 205]. Especially in inflammatory environments, such as found during
chronic wound healing, the amount of bioactive cytokine is even further
decreased through the abundance of proteases and high oxidative stress [51,
206]. To counteract this fast loss of activity, most clinical studies turned to
the application of supraphysiological concentrations to induce the intended
modulatory effects. As an example, early studies for the use of IL-4 as a wound
healing agent had to apply daily amounts of up to 10 µg/cm² to promote
wound closure in diabetic animals over a three week period [199]. However,
such concentrations of cytokines have shown to induce unwanted side effects
in a number of studies and largely reduce the cost-effectiveness of cytokine-
based therapies [17–21].
In this chapter, we explored the aptitude of IL-4- or IL-10-laden starPEG-
heparin hydrogels to polarize murine macrophages in inflammatory environ-
ments as found in chronic wounds. Therefore, the release behavior of non-
covalently conjugated IL-4 and IL-10 from starPEG-heparin hydrogels was
characterized. The effects of the conjugation were analyzed in detail on the
stability of IL-4. Further, the ability of IL-4- or IL-10-laden hydrogels to
modulate macrophage polarization was tested and lastly, the effects of IL-4 or
IL-10 released from starPEG-heparin hydrogels were characterized on their
ability to induce ECM deposition in dermal fibroblasts.
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5.1 results
In the tissue ECM cytokines, such as IL-4 or IL-10, are bound to negatively
charged GAGs to retain and stabilize them against degradation [129, 207].
The strongly negative charged sulfate groups found in most GAGs allow for
high affinity binding to positively charged biomolecules, such as chemokines,
growth factors and other cytokines [131, 174] (Fig. 16). Previous studies
have shown that IL-4 and IL-10 are able to interact with heparin [208–211].
However, soluble heparin is widely unsuitable as a carrier for therapeutic
approaches due to its fast dilution from the application site. Consequently, we
utilized a heparin-based biohybrid hydrogel to reversibly bind the immuno-
modulatory cytokines in a stable in situ cross-linkable polymer network.
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Interleukin 4 Monomer 2INT 15.0 9.26 1.461
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Figure 16 – Chemical Properties of IL-4 and IL-10. (A) Computational model-
ing of cytokine-heparin-interaction based on the structural model published by
Walter et al. [212] and Yoon et al. [213], respectively. (B)Chemical and physical
characteristics of IL-4 and IL-10 based on the primary sequence.
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5.1.1 Reversible complexation of IL-4 & IL-10 to starPEG-heparin gels
As discussed earlier, soluble cytokines in the tissue have a rather limited
half-life in solution. This requires a slow sustained long-term delivery of
active IL-4 and IL-10 from the hydrogel for any future therapeutic applica-
tion. To quantify the release of IL-4 and IL-10 from the scaffolds, starPEG-
heparin hydrogels were loaded with 200 ng cytokine by adding it directly to
the gel mixture before polymerization. For this, maleimide-functionalized
heparin was reacted with thiol-terminated starPEG forming a stable polymer
network [36]. The release in cell culture medium supplemented with 1 mg/ml
BSA was measured by ELISA over two weeks.
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Figure 17 – Binding and release characteristics of IL-4 and IL-10 from starPEG-
heparin hydrogels. Matrices were loaded with recombinant human IL-4 and
IL-10. Release in DMEM supplemented with 1 mg/ml BSA and Proclin 300
was analyzed by ELISA over 168 h. n = 6. (A) Effect of the variation of the
initial cytokine loading concentration (n = 3). (B) Effect of the variation of the
degree of cross-linking at a constant cytokine concentration = 25 ng/ml (n = 3).
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While both cytokines show an initial burst release during the first 24 h, a
considerable fraction remains bound in the polymer network and is subse-
quently slowly released from the material in a nearly linear fashion of ≈0.3%
or ≈0.41% per day for IL-4 and IL-10, respectively (Fig. 17). The total
release after 168 h surmounts 7% of the initially loaded IL-4 and 10% of
the initially loaded IL-10 (Fig. 17, A). Previous studies utilizing starPEG-
heparin hydrogels as a delivery system, demonstrated the correlation between
the initial amount of loaded cytokine and the concentrations subsequently
released [36, 37, 153]. Accordingly, different release profiles could be gener-
ated by adjustment of the amounts of cytokine initially added to the hydrogel
scaffold during polymerization (Fig. 17, A). Thus, the highest initial amount
of cytokine loaded into the scaffold during polymerization, resulted in the
highest total release after 168 h of 4.0 ng or 5.3 ng, for IL-4 or IL-10,
respectively. In contrast, no effect on the cytokine release of the cross-linking
degree (γ) and therefore the material stiffness could be observed (Fig. 17, B).
5.1.2 Stabilizing effects of starPEG-heparin gels on IL-4
As heparin has been known to stabilize other proteins, such as FGF-2,
BMP2, VEGF or somatostatin, against thermal denaturation [207, 214–
217], we characterized the effects of heparin on IL-4’s proteolytic stability
as well as the excess heat capacity, a common indicator of long-term protein
stability [218, 219]. The acquired data revealed an increase in heat capacity
with the addition of heparin to IL-4 (Fig. 18, A). Therefore, the stability
against denaturation, as indicated by the denaturation temperature, shifts
from 50°C with no heparin to 60°C at a concentration of 1.5 mM (molar
ratio IL4:heparin 1:150), which resembles the total concentration of heparin
found in the hydrogel. In addition, the improvement in thermal stability
highly correlates with the increasing amount of heparin with an Coefficient
of determination (R2) of 0.98. In contrast, incubation with the starPEG
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building block to the corresponding concentration found in the hydrogel did
not result in any change in thermal stability (Fig. 18, A).
Besides the thermal and related conformational stabilization, several reports
have suggested a protective effect of heparin-protein interaction against the
degradability of cytokines [208, 209, 220, 221]. Thus, we tested the effect of
the enzymatic degradation of IL-4 bound to the starPEG-heparin hydrogel.
As a heparin-free control, maleimide-terminated starPEG was used to form
hydrogels with comparable physical characteristics such as storage modulus
and network mesh size. IL-4 loaded hydrogels were prepared and incubated at
37°C for 16 h with trypsin as amodel protease. The total amount of remaining
cytokine was determined utilizing an HT-2 cell-based proliferation assay to
directly assess the overall remaining bioactivity.
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Figure 18 – Stabilizing effects of heparin complexation on IL-4. (A) Thermal
stabilization of IL-4 in solution with heparin. The unfolding of the protein with
increasing temperature wasmonitored by differential scanning fluorimetry (n=3).
(B) Bioactivity of IL-4-loaded hydrogels with heparin (HEP-PEG) and without
heparin (PEG-PEG) after 16 h of trypsin digest. After proteolytic degradation,
resulting bioactivity was measured using an HT-2 cell proliferation assay (n=3).
To test the protective effects of IL-4 binding to heparin on bioactivity, IL-4
loaded starPEG-heparin hydrogels were proteolytically degraded by incuba-
tion with trypsin at a molar ratio of 1:1500 (IL-4: trypsin) at 37°C for 16
h. The resulting hydrogels were homogenized and incubated with starved
HT-2 clone A5E cells, a lymphocyte-derived cell line, which requires IL-4
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for cell proliferation [222]. Thus, the remaining amount of active IL-4 and
subsequent activation of the IL-4 receptor can be correlated to the amount
of cell proliferation. While the digest had no impact on the bioactivity of
IL-4 in the starPEG-heparin hydrogels, there was a significant loss of activity
for the IL-4 in gels without heparin (35% activity of corresponding starPEG-
heparin hydrogel; Fig. 18, B). Furthermore, heparin-based hydrogels were able
to retain a higher degree of bioactivity, compared to heparin-free hydrogels,
even without proteolytic degradation. This effect might be explained by the
enhanced long-term stability and therefore resistance against denaturation of
the IL-4 in heparin-based hydrogel over the 16 h digest. These results taken
together with the change in thermal stability indicate a shift in overall cytokine
stability through the complexation of IL-4 onto the GAG component of the
starPEG-heparin hydrogels.
5.1.3 IL-4 & IL-10-laden starPEG-heparin hydrogels modulate macro-
phage polarization
Besides the characterization of the starPEG-heparin-hydrogel as a release
system for IL-4 or IL-10 and the exemplary demonstration of the protective
effects of GAG-based complexation on IL-4, we wanted to evaluate the effects
of the immunomodulatory hydrogels on cell types which are relevant during
the wound healing process. Macrophages can be polarized by IL-4 or IL-10
to the regenerative (M2) state, which plays a major role in the regulation
of inflammation during wound healing as well as in various other disease
involving inflammation [59, 164].
Therefore, primary bone marrow-derived macrophages isolated from C57/-
BJ6 mice were differentiated for 7 days with M-CSF and then challenged
with bacterial LPS. To counteract the pro-inflammatory effects of the bacterial
membrane fragments IL-4-loaded, IL-10-loaded or IL-4+IL-10-loaded hydro-
gels were added into the culture well without any direct contact to the immune
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Figure 19 – Effects of IL-4- and IL-10-loaded starPEG-heparin hydrogels on
macrophages morphology. Macrophages were isolated from C57/BJ6 mice bone
marrow and differentiated for 7 days with M-CSF. Differentiated cells were
treated with LPS (10 ng/ml) and cytokine-loaded hydrogels for 24 h. Scale bar
= 200 µm. (A) Macrophages cultured with empty hydrogel. (B) Macrophages
cultured with IL-4-loaded hydrogel. (C) Macrophages cultured with IL-10-
loaded hydrogel. (D) Macrophages cultured with IL-4+IL-10-loaded hydrogel.
cells. While the LPS treatment induced the typical rounded morphology
found in inflammatory (M1) macrophages (Fig. 19, A), the IL-4-loaded and
IL-4+IL-10-loaded hydrogels were able to induce the spindle-shaped cells
associated with pro-regenerative (M2a) macrophages [223] (Fig. 19, B/D).
In contrast, no effect of IL-10-loaded hydrogels on the cell morphology was
observed (Fig. 19, C). As the macrophage polarization state is even more
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pronounced in the changes in gene expression and the resulting production
of signaling factors, the cellular gene expression levels as well as the cytokines
secreted by the macrophages into the culture medium were further analyzed.
Macrophages can release a wide set of different cytokines and growth factors
to affect other cells in their environment. While inflammatory cytokines,
such as IL-1β, IL-6 and TNF can alert nearby cells to an infection site
and therefore increase the inflammatory response, other chemoattractant
factors, such as macrophage Inflammatory Protein-1 α (CCL3) (MIP-1 α),
MCP-1 or others, attract specific cell types to their source of expression. In
this study, IL-10-loaded hydrogels decreased the amount of inflammatory
cytokines and chemokines most effectively compared to an empty hydrogel
scaffold (Fig. 20, A). In contrast, IL-4-loaded hydrogels did only affect the
cytokine concentrations of IL-1β and MIP-1 α, but could not reduce IL-6,
TNF or RANTES. IL-4+IL-10-loaded hydrogels induced similar decreased
cytokine concentrations compared to IL-10-loaded scaffolds alone for all of
the tested cytokines except of IL-1β, where a cumulative effect decreased
the inflammatory cytokine levels even further (Fig. 20, A). Altogether, the
starPEG-heparin hydrogels loaded with the immunomodulatory cytokines
IL-4 or IL-10 diminished the concentrations of inflammatory cytokines in the
medium, although this effect was mostly based on IL-10 activity. In contrast,
when observing the expression of regenerative macrophage marker genes in
the cell, only the hydrogels containing IL-4 were able to induce the expression
of arginase 1 (Arg1) and chitinase-like 3 (Chil3) [64, 224], while hydrogels
loaded with IL-10 alone had no effect (Fig. 20, B). Furthermore, IL-4-loaded
hydrogels, especially when combined with IL-10, increased the expression of
MCP-1, a factor that in the body attracts macrophages to the wound [183].
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Figure 20 – Effects of IL-4- and IL-10-loaded starPEG-heparin hydrogels on
macrophages protein and gene expression. Differentiated cells were treated with
LPS (10 ng/ml) and cytokine-loaded hydrogels for 72 h. (A) Protein expression
of secreted cytokines and chemokines observed in cell supernatants. (B) Gene
expression of M2 marker genes detected in differentiated macrophages.
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5.1.4 IL-4-laden starPEG-heparin induce collagen deposition in dermal
fibroblasts
As for many cytokines, their effects are not limited to only one cell type or
biological context. Next to the polarization activity of IL-4, it also affects the
induction of ECM protein deposition in dermal fibroblasts [225–227]. As an
increased matrix deposition would be desirable in chronic wounds, where the
ECM production is generally diminished, we decided to investigate the effects
of IL-4+IL-10-loaded starPEG-heparin hydrogels on the collagen deposition
in primary murine fibroblast.
Accordingly, we found an increased deposition of overall collagen inside the
cells but also in the underlying ECM when fibroblasts were treated with IL-4-
loaded starPEG-heparin hydrogels (Fig. 21, B) compared to cells incubated
with the empty scaffolds alone (Fig. 21, A). Moreover, the collagen expression
slightly increased further when IL-4 was combined with IL-10 (Fig. 21, C),
although this effect was not significant. In contrast, no effect of hydrogel
loaded with IL-10 alone could be observed (data not shown). Furthermore,
the IL-4 did not modulate the fibroblast proliferation, which also could
account for the increased collagen deposition (Fig. 21, D).
5.2 discussion
In this chapter, the ability of starPEG-heparin hydrogels to promote the
regenerative (wound healing) phenotypes in macrophages and fibroblasts was
investigated. Therefore, hydrogels were functionalized with immunomodula-
tory IL-4 and IL-10 by harnessing the electrostatic interaction between the
positively charged amino acid residues on the surface of the cytokines and the
negative charged GAG component in the polymer network. By incorporating
heparin as one of the integral building blocks of the hydrogel network, its abil-
ity to bind and release IL-4 and IL-10 can therefore be biomimetically utilized
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Figure 21 – Collagen deposition induced by cytokine-loaded starPEG-heparin
hydrogels. Dermal fibroblasts deposit collagen I matrix after 72 h of culture.
Scale bar = 200 µm. (A) Fibroblasts cultured with empty hydrogel. (B)
Fibroblasts cultured with IL-4-loaded hydrogel. (C) Fibroblasts cultured with
IL-4+IL-10-loaded hydrogel. (D) Statistical analysis of collagen deposition and
cell proliferation (n=3).
for the sustained delivery of the cytokine into the surrounding environment
of the starPEG-heparin hydrogel. In a similar manner, its molecular cousin
in the family of GAGs, heparan sulfate, enables the extracellular matrix in
the body to retain cytokines and growth factors [228]. Consequently, the
GAG-based hydrogel effectively retained a significant fraction of the IL-4 and
IL-10 and gradually released them over time. While the total release could
be modulated by the initial amount of loaded cytokine, the change in the
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cross-linking degree of the polymer network did not influence the release
characteristics. Based on the underlying design principles of the starPEG-
heparin hydrogels, the overall heparin content remains unchanged at different
degrees of cross-linking (γ), allowing for an independent modulation of
the physical and biofunctional properties of the material as demonstrated
before by Freudenberg et al. [35]. In a future therapeutical context, the
high retention and controlled release would enable a sustained delivery of
immunomodulatory cytokines at the application site of the scaffold e.g. the
chronic wound. While enabling a part of the cytokine to be supplied to the
target site, the starPEG-heparin hydrogel also allows for a significant fraction
to be retained and potentially stabilized inside the material.
The complexation of proteins with GAGs, such as heparin, has previously
been described to enhance the stability and subsequently the bioactivity of
various cytokines [131, 220, 229]. This strategy has been widely used for the
stabilization of FGF-1 and FGF-2 against physical and enzymatic degrada-
tion [220, 221]. In addition, recent studies described a more comprehensive
spectrum of proteins that are able to interact with heparin [130]. As such,
IL-4 has been identified to strongly bind to heparin [208, 209, 230] and,
even more importantly, to increase its bioactivity [231]. In consequence, the
protective effects of heparin complexation were exemplarily characterized for
IL-4 in detail. These findings suggest a thermal stabilization of IL-4 when
bound to heparin as well as a proteolytic protection of the cytokine when
complexed inside the starPEG-heparin hydrogel.
Overall, the increased stability of the IL-4 against thermal denaturation
and proteases may support the use of starPEG-heparin hydrogel as a delivery
system for cytokines even in highly proteolytic environments, such as found in
the inflammatory wound milieu. Conversely, most of the current therapeutic
strategies utilize superphysiological bolus applications of cytokines, which
are fast degraded and therefore can only exert their modulatory effect for a
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limited amount of time. For instance Kucukcelebi et al. [199] demonstrated
in previous study in a diabetic rat model the use of IL-4 as a therapeutic
agent to improve the healing outcome of chronic dermal wounds. However,
daily doses of several µg of cytokine per day were necessary to generate a
significant biological effect. The requirement of such non-physiological high
amounts of soluble proteins is based on the fast dissipation and degradation
of soluble cytokines in the body. With the starPEG-heparin hydrogel as a
carrier system, the continuous delivery of bioactive cytokines can overcome
this problem and might, therefore, allow novel clinical approaches for the
use of cytokines, such as IL-4, as a therapeutic agents. While the hydrogel
scaffolds retain a large fraction of the signaling proteins, they nevertheless
release the cytokines at concentrations corresponding to the physiological
levels released from immune cells, which were described to be in the low
nanomolar to picomolar range [232, 233].
During chronic wound healing, the transition from inflammatory phase to
proliferative phase is delayed, which drastically impairs the formation of new
tissue during the repair process. This phenomena goes hand in hand with a
prolonged expression of inflammatory (M1) markers in wound macrophages
as observed in a diabetic chronic woundmodel in several previous studies [234,
235]. In contrast, while mixed macrophage polarization phenotypes were
found during the early healing process in acute (non-diabetic) wounds, cells
shifted to the pro-regenerative (M2) state during later wound healing [196].
Furthermore, Lucas et al. [198] were able to demonstrate the importance
of macrophages during the repair phase, in a murine macrophage depletion
model. Therein, macrophage depletion during the mid-stage of healing
resulted in a severe abrogation of the physiological repair process represented
by hemorrhage, impaired epithelialization and overall delayed healing. These
findings portray the importance of macrophages in the regulation of the repair
cycle and the crucial role during the transition from the inflammatory (M1)
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state to the regenerative (M2) state.
In this study, we analyzed the ability of starPEG-heparin hydrogels loaded
with the immunomodulatory cytokines IL-4 and IL-10 to induce the pro-
healing (M2) phenotype in primary murine macrophages in a highly inflam-
matory environment. While IL-4-laden hydrogels were able to promote an
M2a-specific spindle-shaped phenotype and enhance the gene expression of
M2a marker genes, IL-10-loaded hydrogels were able to decrease the overall
inflammatory signaling response. In a combined approach with dual-loaded
hydrogel, the immunomodulatory cytokines were able to simultaneously elicit
the anti-inflammatory and pro-regenerative polarization in the macrophages.
Contrary to expectations, the expression of MCP-1, a chemokine for the re-
cruitment of macrophages and other immune cells, was increased by the IL-4
treatment. In addition to the role of MCP-1 during the early inflammation,
in which this chemokine recruits macrophages to the wound, it was described
to enhance the IL-4-triggered M2 response by the attraction of basophils and
T-cells, which in turn produce more IL-4 and therefore further promote the
regenerative polarization.
Besides its importance in the polarization of the wound healingmacrophage
response, IL-4 was implicated to enhance ECM deposition in dermal fibrob-
lasts [225–227]. These results demonstrate the ability of IL-4-laden hydrogels
to increase the overall collagen deposition. This effect of the hydrogel might
be of interest in dermal chronic wounds where the balance between ECM
degradation and synthesis is already disturbed. Consequently, the application
of the immunomodulatory cytokines in chronic inflammation could not only
activate regenerative (M2) macrophage polarization, but also enhance the
matrix deposition of fibroblasts in the granulation tissue.
In summary, starPEG-heparin hydrogel scaffolds were functionalized with
the immunomodulatory cytokines IL-4 and IL-10 and characterized for their
release behavior and effects of GAG complexation on the stability of the signal-
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ing proteins. While both cytokines demonstrated different effects on macro-
phages and dermal fibroblasts, their combination provided pro-regenerative
cues to both cell types. As a result, the inflammatory (M1) response of
macrophages was diminished, even though the cells were still triggered by
inflammatory LPS. Additionally, the induction of the regenerative (M2)
phenotype, characterized by the expression of Arg1, Chil3 and the M2a-
specific morphology in macrophages and an increased collagen deposition in
fibroblasts was enhanced by the immunomodulatory hydrogels.
Although, these findings demonstrate a promising application of starPEG-
heparin hydrogels in a wound healing context, the knowledge that can be
gained from an in vitro system is still limited by its severe simplification.
Especially, the wound healing context is a complex confluence of many cell
types, signaling molecules and other environmental cues. Consequently,
based on the results from the in vitro testing, the in vivo application of the
hydrogel system in a suitable wound model would be crucial for further
evaluation of the hydrogels and are therefore intended in the future.
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MODULAT ION OF HUMAN DERMAL F IBROBLAST
PROL IFERAT ION AND DIFFERENTIAT ION
The following chapter contains a revised excerpt of the work previously published
as Watarai et al. [153]. For more information, please refer to the original
publication. Please refer to Chapter 8 for supplementary experimental methods
of the experiments conducted by our collaboration partners and to Chapter 9 for
the full list of contributions from the authors.
Dermal fibroblasts play a crucial role during wound healing [49], such as
the contraction of the wounds and the Clark2006 of main components of the
granulation tissue like collagen fibers and fibronectin ([70, 72]; Section 2.1.2).
In the case of large wounds (e.g. burns) or disturbed wound healing (e.g.
diabetes, infection or chronic venous insufficiency) engineered biomaterials
may provide fast and sterile wound closure and initiate endogenous wound
repair. In that context, biomaterials should form a beneficial micro-milieu
that provides critical functions of the natural extracellular environment sup-
porting adhesion, proliferation and differentiation of dermal fibroblasts. Thus,
cell-instructive hydrogels enabling the independent control of physical cues,
cell adhesion and the delivery of growth factors may be beneficial to control
dermal fibroblast cell fate and therefore modulate wound healing (Fig. 22).
Especially, the administration of TGF-β via hydrogel matrices displaying a
high cytokine binding and release capacity could be advantageous for myofi-
broblast activation, matrix deposition and wound closure.
Therefore, modular hydrogel materials based on star-shaped poly(ethylene
glycol) (starPEG) and heparin (Section 2.4.6) were investigated as an adapt-
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Figure 22 – Schematic view of cell-instructive starPEG-heparin hydrogels to
induce myofibroblasts differentiation. (A) TGF-β is reversibly conjugated to the
hydrogel scaffold and released over time to induce myofibroblast differentiation.
(B) Network structure of the starPEG-heparin hydrogel, composed of RGD-
modified heparin cross-linked through MMP-sensitive peptide linkers to 4-arm
starPEG. Electrostatic interactions between heparin and TGF-β allow for pro-
tection and retention of the cytokine in the hydrogel and subsequent sustained
release.
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able material to support growth and differentiation of human dermal fi-
broblasts. As a key feature, heparin allows the reversible complexation of
cytokines and mediators for stimulating cells involved in the healing pro-
cess [36, 37, 154]. Especially the electrostatic interaction of specific amino
acids of the TGF-β molecule with heparin enables the efficient administration
and protection of the protein as it might be beneficial for wound healing
application [236–238].
6.1 results
6.1.1 Reversible complexation of TGF-β to starPEG heparin gels
The local and sustained delivery of soluble signal molecules is a fundamental
requirement for many regenerative approaches [239, 240]. Therefore, hydro-
gel materials may serve as depots for bioactive proteins, preserving their sta-
bility and function and enabling sequential release for extended time periods.
StarPEG heparin gels were shown to bind and release a plethora of heparin-
binding growth factors, such as VEGF, FGF-2 and bone morphogenetic
protein 2 (BMP2) [34, 154, 241]. In here, we functionalized starPEG heparin
hydrogels with human TGF-β. For this, we utilized the strong interaction of
heparin with TGF-β, based on its two consensus heparin-binding regions at
26 and 60 positions of the biomolecule [236, 238].
First, the ability of the hydrogels to bind and release different amounts
of TGF-β (0.5, 1.0 and 2.0 µg/ml loading concentration) was investigated
by ELISA (Fig. 23) exemplary for an intermediate cross-linking degree (γ =
3, storage modulus of 10 kPa). Independently of the loading concentration
an immobilization efficiency of 96–97% was found (Fig. 23, A). The release
kinetics show an initial burst release during the first 24 h followed by a slower,
continuous release over the whole time course of the measurement. The
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Figure 23 – Binding and release characteristics of TGF-β from starPEG-heparin
gels. starPEG-heparin hydrogel-coated glass coverslips were loaded with recom-
binant human TGF-β. Release in DMEM supplemented with 1 mg/ml BSA
and Proclin 300 was analyzed by ELISA over 168 h. n = 6. (A) Immobilization
efficiency of TGF-β onto the starPEG-heparin hydrogel. (B) Effect of the
variation of the initial TGF-β loading concentration (n = 3). (C) Effect of the
variation of the degree of PEG cross-linking at a constant TGF-β concentration
= 0.5 µg/ml (n = 3). (D) Overall relative cumulative release n = 12.
amount of free TGF-β detected in the medium directly correlates with the
initial concentration loaded onto the hydrogels (Fig. 23, B).
Further on, the influence of the cross-linking degree on the release of TGF-β
was investigated. Therefore, hydrogels with a starPEG to heparin ratio of γ
= 3 and 6 (corresponding to 10 and 16 kPa storage modulus), but a constant
amount of heparin were loaded with a cytokine concentration of 1 µg/ml.
In contrast to the loading concentration, there was no significant influence
of the cross-linking degree on the amount of TGF-β sequestered from the
scaffolds (Fig. 23, C). Overall 9.8% of the total immobilized TGF-β were
released after the first 168 h of incubation (Fig. 23, D).
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6.1.2 Cell attachment, spreading and proliferation
To evaluate the effects of the starPEG-heparin hydrogels on fibroblast
attachment, spreading and proliferation the cells were analyzed at several time
points after seeding. Soft starPEG-heparin gels with a Young’s modulus of
3 kPa in several modifications, such as RGD adhesion peptides or ±MMP-
cleavable peptide linkers (CL) were seeded with fibroblasts pre-grown on tissue
culture plastics. In general, RGD peptides supported attachment of dermal fi-
broblasts on starPEG-heparin gels. At very early time points dermal fibroblasts
adhered to all hydrogels independent of stiffness and biomolecular function-
alization (Fig. 24, B). However, clear differences were detectable showing a
significant dependency of attached cell numbers and cell spreading on the pres-
ence of RGD-peptides onto the hydrogels 48 h after seeding (Fig. 24, A/C).
After 96 h of culture F-actin cytoskeleton was well formed in all cells grown
on starPEG-heparin gels containing RGD-peptides (Fig. 24, B). Similarly, on
stiffer hydrogels (30 kPa Young’s modulus) the presence of RGD peptides was
essential for successful cell attachment and spreading (data not shown). A
tremendous increase in cell proliferation on hydrogels functionalized with the
adhesion peptide RGDwas detected using XTT-assays (Fig. 24, D).The intro-
duction of CL-peptides supported cell proliferation after 48 h of culture, but
resulted in decreased cell proliferation rates after 72 h of growth (Fig. 24, D).
When comparing fibroblast growth on RGD-containing starPEG-heparin
hydrogels of different stiffness we detected increased proliferation on softer
starPEG-heparin gels compared to stiffer variants, whereas a similar behavior
like for collagen-coated glass slides was found for the stiffer gels (Fig. 24, E).
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Figure 24 – Culture of dermal fibroblasts on starPEG-heparin hydrogels. (A)
Cells were grown for 48 h on starPEG-heparin hydrogel-coated coverslips
(Young’s modulus 3 kPa) with different modification (± RGD peptide, ± CL-
peptide). Scale bar = 200 µm. (B) Staining with Phalloidin-Alexa488 and DAPI
(nuclei) 96 h after seeding. Scale bar = 50 µm. (C) Cell number determined at
three time points using the XTT assay. n = 3. *p < 0.05, **p > 0.05, ***p <
0.001. (D) Comparison of cell proliferation relative to collagen control. n = 8.
Data contributed by Anderegg et.al. Watarai et al. [153].
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6.1.3 Matrix deposition by fibroblasts grown on starPEG-heparin hydro-
gels
Fibroblasts essentially contribute to ECM formation in their tissues of
residence. In the dermis, they release pro-collagens, glycosaminoglycans,
proteoglycans, fibronectin and other components of the ECM [71]. During
wound healing fibroblasts and myofibroblasts are essential cells for wound
closure and synthesis of the provisional as well as remodeled scar matrix. Here,
we tested whether fibroblasts cultured on starPEG-heparin hydrogels deposit
ECM on these substrates. After 7 days of culture, a fibroblast-derived ECM
mesh work containing collagen I and fibronectin could be detected on the
starPEG-heparin hydrogels after lysis of the cells (Fig. 25).
A Decelularized matrix
fibronectin merge
ctrl
colagen I
Colagen stain
control TGFβ
B
Matrix depositionC
Figure 25 – Fibroblasts deposit a matrix containing collagen I and fibronectin
on starPEG-heparin hydrogels. Dermal fibroblasts were cultured for 7 days in
DMEM with 10% FCS on hydrogels (3 kPa, RGD functionalized, no MMP-
cleavable peptides) and deposited ECM was analyzed. (A) The cells were lysed
resulting in a layer of decellularized extracellular matrix. Scale bar = 100
µm. (B) Collagen in the ECM stained with Sirius red. (C) ECM stained by
immunofluorescence with antibodies against collagen I (mab 183492, abcam) or
(D) fibronectin. Scale bar = 50 µm. Inserted picture shows secondary antibody
control. Data contributed by Anderegg et.al. Watarai et al. [153].
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6.1.4 Degradation of starPEG-heparin hydrogels
Hydrogel degradation and remodeling were tested performing a degrada-
tion assay with differentiated dermal fibroblasts. In detail, dermal fibroblasts
were seeded on soft starPEG-heparin hydrogels (3 kPa storagemodulus, RGD-
functionalized) cross-linked with or without MMP-sensitive CL-peptides.
Myofibroblast differentiation was induced by TGF-β pre-loading and possible
degradation effects were followed by Atto-488 labeled heparin (red) as one of
the gel building blocks. The cells were cultured for 72 h and stained for F-
actin (green) to visualize the cell body and counterstained by DAPI for nuclei
(blue). A strong internalization of labeled heparin into the myofibroblasts
could be detected in the case of the starPEG-heparin gels cross-linked with
CL, while nearly no heparin could be detected in cells grown on top of the
CL-hydrogels. Although the scaffold was degraded (Fig. 26), there was no
immigration of the cell body into the scaffold detectable.
A B RGD+ CL+RGD+ CL-
Figure 26 – Degradation assay of starPEG-heparin gels. TGF-β-stimulated
dermal fibroblasts (differentiation induced by TGF-β-gel pre-loading) grown on
starPEG-heparin hydrogels functionalized with RGD-peptides cross-linked with
or without MMP-cleavable peptides (± CL-peptide). Degradation effects and
internalization of heparin into the myofibroblasts are seen in the presence of
MMP-cleavable linker only. F-actin (green), Heparin-Atto488 (red) and DAPI
(blue) were visualized by staining. Scale bar = 20 µm.
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6.1.5 TGF-β-laden starPEG-heparin that efficiently induces myofibrob-
last differentiation
During wound healing, dermal fibroblasts have to differentiate to myofi-
broblasts expressing typical marker genes like collagen I, the splice variant of
fibronectin ED-A and the special actin form α-smooth muscle actin (α-SMA)
which becomes integrated into stress fibers of wound contracting myofibrob-
lasts. Substrate stiffness and stimulation by TGF-β essentially contribute to
this differentiation [70, 73]. For a possible application as a wound dressing,
hydrogel-conjugated TGF-β should be able to trigger this myofibroblast dif-
ferentiation. Following the results of hydrogel functionalization we tested
if hydrogel TGF-β released from the hydrogel could be used to stimulate
myofibroblast differentiation. Thus, we compared the biological effect of
released TGF-β and soluble added TGF-β on dermal fibroblasts grown on
starPEG-heparin gels. For this purpose RGD-peptide functionalized starPEG-
heparin gels with a Young’s modulus of 30 kPa were used in order to provide
the mechanic stimulus for myofibroblast differentiation. Based on the release
data (Fig. 23) the initial loading concentration of TGF-β was adjusted to
release TGF-β (10 ng/ml) after 24 h. TGF-β induced typical target genes
like collagen I and palladin with comparable efficiency after addition in
soluble form as well as after loading to the starPEG-heparin gels in dermal
fibroblasts (Fig. 23, A).The signal for ED-A fibronectin was even significantly
higher for hydrogel-released TGF-β compared to the soluble control.
For differentiation of dermal fibroblasts to myofibroblasts, the induction
of the respective target genes is essential (Fig. 27, A). Furthermore, the in-
tegration of α-SMA into actin stress fibers is required for the characteristic
phenotype. In vitro, the α-SMA incorporation can be observed in a fraction of
dermal fibroblasts in a culture dish [73, 242]. We cultured dermal fibroblasts
on RGD-containing starPEG-heparin gels with two different Young’s moduli
93
modulation of human dermal fibroblasts
Gla
ss
Co
l1A
RG
D+
so
l. T
GF
β1
RG
D+
co
nj.
 TG
Fβ
1
Gla
ss
Co
l1A
RG
D+
so
l. T
GF
β1
RG
D+
co
nj.
 TG
Fβ
1
Gla
ss
Co
l1A
RG
D+
so
l. T
GF
β1
RG
D+
co
nj.
 TG
Fβ
1
Figure 27 – Induction of myofibroblast differentiation by TGF-β on starPEG-
heparin hydrogels. (A/B) Cells were cultured for 48 h under stimulation with
soluble (10 ng/ml) or hydrogel conjugated TGF-β (loading adjusted to reach
a similar concentration of 10 ng/ml in the supernatant after 48 h). Scale bar
= 20 µm. (C) Stimulated gene expression compared to the untreated control
cells (reference line) is shown on glass, collagen or hydrogels surface with soluble
TGF-β or pre-conjugated TGF-β. n = 4, **p < 0.01. Data contributed by
Anderegg et.al. Watarai et al. [153].
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– 3 and 30 kPa. Cells spread more efficiently on the softer starPEG-heparin
gels. However, TGF-β drove differentiation as seen in Fig. 23, which was
typical for cells grown on starPEG-heparin gels of both storage moduli. The
differentiation was detected as increased expression of α-SMA (red) and inte-
gration of this actin variant into F-actin stress fibers (red–orange, Fig. 27, B).
Furthermore, the integration of Palladin (white, 140 kDa) into F-actin fibers
(red) upon stimulation with TGF-β was detected (Fig. 27, C; [243]). TGF-β
was effective to induce these differentiation-associated changes (Fig. 27) both
when added to the medium and pre-loaded to the hydrogels.
These findings show that starPEG-heparin hydrogels are capable to bind
efficiently and release biologically active TGF-β. Furthermore, starPEG-
heparin gels support proliferation, matrix deposition and remodeling and
mediator-driven differentiation of dermal fibroblasts in vitro.
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6.2 discussion
In this study, we investigated if cell-instructive starPEG-heparin hydrogels
could be utilized to control dermal fibroblast cell fate. Notably, the effective
administration of TGF-β from the hydrogel matrices [131] was expected
to be beneficial to control myofibroblast activation, matrix deposition and
finally wound closure. Therefore, starPEG-heparin hydrogels with different
mechanical properties were modified either by the introduction of cell adhe-
sive RGDpeptides [147] or additionally by cross-linking withMMP-cleavable
peptide linkers [244]. Soft (Young’s modulus ~3 kPa) gels roughly resemble
the stiffness of the resting dermis whereas stiffer (Young’s modulus ~30 kPa)
hydrogels reflect the situation of granulation or scar tissue [245, 246]. Many
cells respond to the stiffness of the surroundingmatrix [107] and especially the
TGF-β-driven differentiation of dermal fibroblasts to myofibroblasts during
wound healing depends on physical signals from thematrix [72, 73, 242]. The
independent modulation of all these parameters seems to be crucial to identify
material properties capable of regulating dermal fibroblast differentiation that
might be beneficial to promote wound healing.
In line with previous results for other heparin-binding growth factors [34,
37, 241] we could demonstrate that physiologically active TGF-β can be
reversibly conjugated to the starPEG-heparin hydrogels. A strong interaction
between heparin with TGF-β based on its high amount of basic amino acids
has been reported in the past [236, 238]. While the cross-linking degree and
thus stiffness did not influence the release of the 12 kDa TGF-β, the initial
loading concentration of the cytokine could be utilized to tune release kinetics.
This behavior is in line with the binding and release of other similarly sized
growth factors to heparin previously reported [34, 37, 241].
For hydrogels with various cross-linking degrees, the heparin concentration
in the swollen network and thus the amount of bioactive component is
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constant in all hydrogel types [34]. Thus, the observation of similar release
characteristics for the different stiff matrices confirms the possibility to decou-
ple actively biomolecular functionalization and physical characteristics of the
gel materials as previously described [34].
In contrast, the long-term release profiles were strongly affected by the
initial loading concentration. Thus, the release of an active cytokine from
such a material could be easily adjusted to the specific biological or clinical
demands. This behavior was exemplarily used to adjust the released amount
of TGF-β to the concentration of approx. 10 ng/ml used as a standard con-
centration for in vitro cultures to stimulate dermal fibroblast differentiation
into myofibroblasts [72].
Overall, the hydrogel matrices allow a sustained and customized release
of TGF-β over time courses relevant for myofibroblast differentiation and
wound healing applications.
In line with previous reports the starPEG-heparin hydrogels without RGD-
modification show reduced cell attachment also for dermal fibroblasts [244].
RGD peptides enable cell adhesion and spreading on various biomaterials
that display initially low cell binding capacities [247, 248]. Independent
of the stiffness (3 or 30 kPa), starPEG-heparin hydrogels required the in-
corporation of RGD peptides to promote fibroblast spreading and allow for
subsequent measurement of their proliferation. XTT data support the notion
that starPEG-heparin hydrogels functionalized with RGD peptides support
dermal fibroblast adhesion and subsequent proliferation similarly to collagen-
coated surfaces irrespective of their stiffness. Now, primary adhesion was the
clue for later efficient proliferation and therefore, efficient proliferation was
detected on pro-adhesive starPEG-heparin hydrogels only.
The introduction of MMP-cleavable peptide linkers did not modify the
adhesive capacities of the hydrogels. However, the proliferation of dermal
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fibroblasts was modified by the addition of CL in different manner. The
introduction of CL probably supported cell proliferation for initial 24 h
most efficiently, but later on these cell cultures did not further increase their
proliferative activities. Therefore, the addition of RGD peptides was essential,
but sufficient for effective seeding and proliferation of dermal fibroblasts on
starPEG-heparin hydrogels.
Moreover, the introduction ofMMP-cleavable linkers into starPEG-heparin
hydrogels enables the cell-responsive remodeling by dermal fibroblasts. The
peptide sequence utilized in this material is based on a studies by Nagase
and Fields [146] and Lutolf et al. [147] aiming for fast degradation by
MMP-2, MMP-3 and MMP-9; key players in the matrix remodeling. The
spread dermal fibroblasts slowly degraded the underlying starPEG-heparin
hydrogel and internalized the heparin within the cell body. In contrast to
the focused cell penetration of endothelial cells forming vascular structures as
previously described [37, 249], the dermal fibroblasts degrade the hydrogel
more slowly and homogeneously by attaching onto the outer surface of the
scaffold followed by the planar remodeling. This result points to a function-
dependent degradation mechanism of the fibroblasts that should remodel the
wound body homogeneously during the granulation phase of wound heal-
ing [71] that is expected to be beneficial for a possible application as a wound
dressing. Furthermore, dermal fibroblasts deposit their own ECM on the
starPEG-heparin hydrogels resulting in a natural, tissue-compatible interface
between the hydrogel material and the surrounding tissue. In summary,
these experiments revealed that starPEG-heparin hydrogels can be tuned to
support the adhesion and proliferation of dermal fibroblasts as well as matrix
deposition and remodeling.
Gene expression analysis revealed that dermal fibroblasts grown on starPEG
heparin hydrogels respond physiologically to TGF-β – an essential modulator
of myofibroblast differentiation during wound healing [250]. Similarly to
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collagen-coated slides providing a natural substrate for fibroblasts, this growth
factor induced the expression of collagen I(α1) and ED-A fibronectin in the
dermal fibroblasts grown on starPEG-heparin hydrogels of any modification.
TGF-β was active both in soluble form and after pre-adsorption to the
starPEG-Heparin hydrogels. Interestingly, the sustained release of low con-
centrations of TGF-β was effective in inducing target genes when the initially
released “burst” amount of TGF-β (Fig. 23) was removed before seeding (data
not shown). Thus the starPEG-heparin hydrogels resemble an effective depot
for active TGF-β. The hallmarks of myofibroblast differentiation could also
be observed at protein level when α-SMA and Palladin were integrated into
F-Actin fibers of differentiating dermal fibroblasts in agreement with other
studies [49, 70, 72, 251]. Overall, the reported effective administration of
pre-conjugated TGF-β might be used to pave the way to customized func-
tionalized wound dressings allowing for local and sustained TGF-β release
and subsequently efficient myofibroblast activation.
Customized starPEG-heparin hydrogels, adjusted with respect to biomolec-
ular functionalization and degradability and effectively administering cytokines,
can control the fate of human dermal fibroblasts in vitro. Besides adhesion and
proliferation, the wound healing relevant differentiation into myofibroblasts
was achieved by precise adjustment of hydrogel delivered TGF-β, offering
valuable options for skin tissue engineering applications and novel wound
dressing materials.
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GENERAL DISCUSS ION
In this work, we explored the opportunities of starPEG-GAG hydrogels to
modulate the hallmarks of chronic wound development, such as the prolonged
inflammation, increased cell influx and delayed proliferative phase. Patients
afflicted with chronic wounds suffer from pain and resulting disabilities, in ad-
dition to psychological stress and poor quality of life. As these chronic wounds
represent a challenge for conventional wound treatment, novel materials for
the targeted treatment of these severely inflamed wounds are urgently needed.
While inflammation is an essential step of the initial wound healing process,
it normally subsides within a few days allowing for an enhanced tissue prolif-
eration and wound closure. However, in the chronic wound environment,
the inflammatory response persists for a prolonged time period, characterized
by the elevated numbers of neutrophils and macrophages, which remain in
the wound for weeks and months [44, 85, 86]. The abundance of immune
cells leads to highly elevated concentrations of inflammatory cytokines and
chemokines attracting still more immune cells into the wound area [87]. In a
cycle of immune cell influx and the secretion of cytokines and chemokines,
a persistent inflammatory self-reinforcing feedback loop is created, conse-
quently preventing any subsequent tissue proliferation.
In addition, large amounts of tissue degrading proteases (e.g. elastase or
MMPs) and reactive oxygen and nitrogen intermediates are released into the
wound bed, as part of the microbiocidal activity of the immune cells, causing
a severe proteolytic environment, which is further enhanced by the absence of
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protease inhibitors, such as TIMPs, commonly found in acute wounds [2, 88,
89]. As a consequence, protein-based signaling molecules or newly formed
ECM proteins are degraded in this destructive environment. Thus, mitogenic
signaling factors, mostly growth factors and other regenerative cytokines,
are highly reduced in chronic wounds and can therefore not perform their
endogenous functions to promote cell proliferation and advance the process
of wound healing [90].
In essence, the pathogenic state found in chronic wounds is characterized
by a pronounced imbalance between inflammatory and proliferative signaling
molecules based on a persistent inflammatory environment, which prevents
tissue formation and subsequent wound closure. Whilemost current therapies
try to support the healing process through a beneficial healing environment
and the application agents that promote tissue proliferation, they do not deal
with the causal persistent inflammation. We therefore developed and tested
different strategies to control the different stages of wound healing with a focus
to the prolonged inflammatory phase going in parallel with a modulation of
proliferative signals based of one modular starPEG-GAG hydrogel material -
that should ultimately allow to develop most efficient wound dressings for the
treatment of chronic wounds (Fig. 28).
To address the underlying problem of prolonged inflammation, elevated
inflammatory signaling, excessive immune cell influx and the resulting lack
of proliferation, chemokine-scavenging GAG-based hydrogels were devel-
oped and characterized for their immunomodulatory properties (Chapter 4).
Chemokines comprise a class of signaling molecules that selectively recruit
and activate cells during inflammation [164]. In the wound healing process,
these signaling molecules are first released by damaged cells at the site of injury
to generate chemoattractant gradients initiating the invasion of immune cells,
a process which is essential for the early inflammatory phase of acute wound
healing. However, as described earlier, the overexpression of chemokines can
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Figure 28 – Model of acute and chronic wound healing pathophysiology.
Adapted from Mast and Schultz [51]. Copyright permission from John Wiley
and Sons.
cause an uncontrolled influx of immune cells, which drives the production of
inflammatory mediators, eventually leading to the development of a chronic
wound [166–168].
The interaction between chemokines and the GAG components of the
ECM has been well characterized [40, 79, 164]. In the body the binding
to the tissue matrix enables chemokines to establish long-ranging chemokine
gradients that efficiently control activation andmigration of immune cells [41,
42]. By adapting nature’s principle: the strong affinity of chemokines to
heparin, the GAGwith the highest charge density known in nature [172], can
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be utilized to successfully scavenge and inactivate these molecules. Therefore,
heparin-based hydrogels were engineered to control the pro-inflammatory
chemokine gradients in the wound environment. When applied to murine
dermal wounds massive amounts of chemokines were scavenged with high
affinity within the polymer scaffold and depleted from the inflammatory
wound. Consequently, the recruitment of further immune cells was dimin-
ished and, as a secondary effect, the overall expression of inflammatory cy-
tokines, such as TNF or IL-1β, was largely reduced. Through the integration
of heparin as a main building block of the hydrogel network, an unmatched
high capacity for chemokine binding could be achieved. This allows the
hydrogel to act as an inflammatory sink for an extended period of time, while
simultaneously providing a moist environment promoting wound healing.
Moreover, through the selective desulfation of the GAG building block of
our polymer network, we could fine-tune the overall scavenging activity of the
hydrogel scaffolds, allowing for a highly controlled anti-inflammatory activity
of the hydrogel scaffolds. In contrast to current therapeutic approaches,
which focus mostly on the promotion of tissue proliferation, rather than
addressing the underlying inflammatory imbalance in the chronic wound,
we demonstrated the anti-inflammatory effects of starPEG-GAG hydrogels
through the binding of chemokines and the subsequent neutralization of their
chemoattractant activity in the wound (Fig. 28).
While a prolonged inflammation, as found in chronic wounds, might
impair healing, it plays a vital role in the overall repair process. For instance,
the early influx of immune cells including neutrophils and macrophages,
plays a major role in the body’s defense against bacterial infections. Be-
sides their microbiocidal activity, macrophages have been shown to fulfill a
broad spectrum of other functions during the wound healing process. More-
over, they have been demonstrated to be implicated in the control of the
transition from inflammatory to the proliferative phase [195, 197, 198].
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In consequence, when macrophages were depleted from the wound in a
mouse model during this stage, a severe abrogation of the physiological repair
process is induced [198]. Depending on the signaling molecules in their
environment, macrophages can switch between several functional subsets,
acting in response to the current requirements of the healing wound [59].
During the acute wound healing, macrophages shift from mixed macrophage
polarization phenotypes in the early healing process to the pro-regenerative
(M2) state in later wound healing [196]. This functional subset, in contrast
to the inflammatory (M1) macrophages, promotes immunoregulation, tissue
repair and constructive tissue remodeling. Not surprisingly, a prolonged M1
signature can be found in a diabetic model system for chronic wounds in mice
and rats, where the depletion of regenerative (M2) macrophages results in a
persistent inflammation and delayed healing [196, 234, 235]. Moreover, as
macrophages respond to their wound environment, they release growth factors
and other cytokines to regulate the behavior of the other cell types involved
in the repair process. As such, macrophages act as a central regulator and are
therefore able to orchestrate the natural sequence of repair processes in the
wound.
On the basis of these findings, immunomodulatory hydrogels were de-
veloped, which promote the polarization of regenerative (M2) macrophages
under inflammatory conditions, therefore supporting the resolution of the
inflammation and promoting subsequent healing (Chapter 5). Previous
studies have demonstrated the beneficial effects of IL-4 and IL-10 treatment in
murine wounds[199]. Those two immunomodulatory cytokines can induce
regenerative (M2) macrophages and thus influence wound closure and quality
of the newly formed tissue [199–202]. However, as with most cytokines,
the excessive levels of proteases during the inflammatory healing phase results
in a fast degradation and consequently a reduced bioactivity of the signaling
proteins [51, 206]. Previous therapeutic approaches have tried to counteract
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the short half-life with supraphysiological concentrations of cytokines to still
induce the desired effect. Yet, such high levels of signaling molecules can
induce unwanted side effects as demonstrated in a number of studies and re-
duce the cost-effectiveness of most cytokine-based therapies [17–21]. A local
and sustained delivery of soluble signaling molecules utilizing starPEG-GAG
hydrogels might resolve this problem [239, 240]. In our study, IL-4 and IL-10
were successfully retained in the scaffold and controllably released over several
weeks, through the complexation of the immunomodulatory cytokines with
the GAG component of the starPEG-GAG hydrogels. The conjugation of
the cytokines to the GAG building block is based on electrostatic interactions
between the negatively charged sulfate groups of the carbohydrate and the pos-
itively charged surface of the proteins. Therefore, cytokines can be loaded in
the hydrogel scaffold without additional chemical modification, consequently
allowing for the full preservation of the signaling molecule’s endogenous
bioactivity. Moreover, while bound to the GAG component inside the poly-
mer network, the cytokines were stabilized against proteolytic and thermal
degradation. When tested on their immunomodulatory effects, the IL-4
and IL-10-laden hydrogels diminished the inflammatory (M1) polarization
in macrophages and in turn promoted the polarization of regenerative (M2)
macrophages, even under highly inflammatory conditions. In addition to the
immunomodulatory activity on macrophages , the functionalized hydrogels
largely increased the deposition of ECM components from dermal fibroblasts,
another cell type relevant during the wound healing process. Therefore, in
here a starPEG-GAG hydrogel has been customized to address the major
aspects of prolonged inflammation in a modular way: scavenging of pro-
inflammatory signals and the independent release of immunomodulatory
cytokines to efficiently intervene with the disrupted signaling environment of
the chronic wound and enhances the regenerative response in cells significant
for the body’s repair cycle (Fig. 28).
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During the later repair phase of the wound, myofibroblasts play a prudent
role in the regulation of the healing process andmaintenance of the skin home-
ostasis. They originate from fibroblasts, which are recruited from the local
connective tissue into the granulation tissue, where TGF-β, in concert with
a stiff matrix, promotes their differentiation [70, 73, 252]. Myofibroblasts
are able to collectively contract their surrounding matrix through a cytoplas-
mic microfilamentous apparatus composed of large stress fibers of actin and
myosin [72]. In addition, these cells largely contribute to the formation of
new tissue through the extensive synthesis of the main components of the
granulation tissue including collagen fibers and fibronectin [70, 72], which
eventually replaces the provisional fibrin matrix and is later remodeled into
scar tissue. With their broad functional responsibilities, myofibroblasts act as
the essential key player during the proliferation phase of wound healing.
Customized starPEG-heparin hydrogels adjusted with respect to material
stiffness, degradability and biomolecular functionalization, were optimized to
efficiently promote the differentiation of myofibroblasts (Chapter 6). Hydro-
gel scaffolds with varying cross-linking degree, adhesion peptides and MMP-
cleavable peptide linkers peptides were tested on the induction of typical
differentiation markers in the dermal fibroblast (e.g. α-SMA, Palladin or ED-
A fibronectin). In particular, the administration of pre-conjugated TGF-β
and the subsequent presentation to the cells at physiological levels dramatically
enhanced myofibroblast differentiation and ECM deposition. Overall, the
reported hydrogel platform could thus be used to precisely control the fate
of human dermal fibroblasts in vitro, such as adhesion, proliferation, ECM
deposition and the wound healing relevant differentiation into myofibrob-
lasts (Fig. 28). Thus, the developed material might offer valuable options for
skin tissue engineering applications and novel wound dressing materials.
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7.1 summary and conclusion
The progress in regenerative medicine has offered a number of new tools to
control cell behavior, support regeneration and replace lost tissue functions.
Although considerable efforts have been made to develop novel strategies to
aid tissue repair in chronic wound, the number of therapies translated into
clinical practice has been limited. A major challenge for the development of
new therapies is presented by the high complexity associated with the related
pathophysiology of chronic wounds. The combination of multiple cell types,
signaling molecules and their interaction with the surrounding tissue matrix,
together with the complex hierarchical and spatiotemporal regulation of the
body’s repair process makes the design of therapeutic strategies challenging.
A material that could successfully support the healing in impaired wounds
would therefore have to modulate several factors of the wound environment
simultaneously.
The aim of this thesis was to explore the potential starPEG-GAG hydrogels
as a bioactive wound dressing material for the treatment of chronic wounds
b<addressing the multiple aspects of this pathogenic state We therefore pur-
sued different complementary strategies to optimize the hydrogel material for
the engineering of the various dysregulated processes of the chronic wound
physiology.
First, the activity of starPEG-GAG hydrogels to scavenge inflammatory
chemokines and consequently modulate the inflammatory response in the
wound was demonstrated. Based on the high affinity within the hydrogel,
chemokines were depleted from the wound, stopping the further recruitment
of immune cells and enabling to the resolution of the overall inflammation.
Second, starPEG-GAG matrices were functionalized to administer the
anti-inflammatory IL-4 and IL-10. The high GAG content of the matrix in
particular is the key for the protection and sustained delivery of both cytokines,
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which are crucial for the resolution of inflammation and the support of
regenerative processes during wound healing. We could therefore demonstrate
the ability of the IL-4 and IL-10-releasing hydrogel matrix to decrease the
inflammatory response of immune cells and to induce their regenerative
polarization.
Finally, starPEG-GAG hydrogel scaffolds, adjusted with respect to physical
and biomolecular properties to effectively administer cytokines, were shown
to control the fate of human dermal fibroblasts in vitro. Besides adhesion
and proliferation, the support of wound healing relevant differentiation
into myofibroblastswas achieved by precise adjustment of hydrogel delivered
TGF-β, offering valuable options for skin tissue engineering applications and
novel wound dressing materials.
In essence, the introducedmulti-functional biohybrid hydrogels were demon-
strated to modulate the various processes involved in the pathophysiology
of delayed dermal healing and might therefore represent a promising novel
wound dressing capable for the regulation of chronically inflamed wounds.
7.2 future perspective
While the starPEG-GAG hydrogels were found to be an effective tool
to modulate different aspects of the chronic wound environment, most of
the testing was done utilizing in vitro model systems. As of now, only the
scavenging potential of the starPEG-GAG hydrogels was verified in an in
vivo wound healing context. With the high complexity of the wound healing
process the initial testing in in vitro model systems offered the benefit of a
higher degree of control over the testing conditions and allowed for a larger
scope of characteristics to be optimized. Nonetheless, the in vivo evaluation of
the IL-4- and IL-10-loaded hydrogel scaffolds for the immunomodulation of
the immune cells in the wound as well as the TGF-β-loaded matrices for the
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promotion of myofibroblast, might deepen the understanding of the benefits
of starPEG-GAG hydrogels as a wound dressing.
In addition, the combination of differently functionalized hydrogels, might
offer even better tissue repair results and should therefore be examined. Most
wound dressing materials are replaced within three days after their initial
administration to the injury. This treatment regime enables the consecu-
tive application of specifically engineered materials for different stages of
wound healing process. While a non-degradable material with high heparin
content could be applied as a sink for chemokines during the peak of the
inflammatory phase, an immunomodulatory-functionalized material could
be utilized to subsequently facilitate the transition from inflammation to
proliferation. Thereafter, the proliferative phase might be enhanced by the
hydrogel-based application of TGF-β at physiological levels from a degradable
scaffold. Thus, the different functionalities could be utilized to modulate the
wound environment in a highly controlled manner depending on the current
need of the patient.
Moreover, using the options to extend the set of modulators incorporated
in the polymer matrices, other cytokines such as the highly anti-inflammatory
Interleukin 1 receptor antagonist (IL-1RA) could be utilized to directly block
the inflammatory activation on cell-surface receptors on the immune cells.
This cytokine, marketed as Anakinra (Kineret®), is secreted by various types of
cells including various immune cells and epithelial cells as a natural inhibitor
of the pro-inflammatory IL-1β [253, 254]. In a related manner a number
of anti-cytokine antibodies have been developed for the immunosuppres-
sion of inflammatory cytokines, such as infliximab for the neutralization
of TNF [255]. They demonstrate efficient anti-inflammatory capabilities
through their high-affinity binding and the resulting systemic depletion of
the inflammatory cytokines from the body. However, due to these extensive
systemic effects of the immunosupressive drugs, severe side effects, such as
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opportunistic infections, might be induced [256]. Combined with the intrin-
sic anti-inflammatory effects, the complexation of such drugs in the hydrogel
system might largely expand the scope of factors that can be scavenged by
the hydrogel scaffold and might in addition enable more advanced delivery
strategies of responsive anti-inflammatory therapeutics at the target site. Thus,
non-covalently tethered to starPEG-GAG hydrogels, these anti-inflammatory
cytokine therapeutics could either be slowly released at physiological con-
centrations from the scaffold or with specific protease-sensitive linkers be
released in response to the proteolytic burden of the chronic inflammation.
As such, future studies could evaluate a responsive system, which releases anti-
inflammatory molecules on demand into the chronic wound or another target
tissue of the broad range of inflammatory disease such as multiple sclerosis or
rheumatic arthritis.
As a more advanced approach, the embedding of patient derived cells in
the hydrogel matrix might benefit the wound healing result. The Michael
addition-based cross-linking chemistry was previously successfully utilized to
culture cells inside the starPEG-GAG hydrogels for a prolonged period of
time [257]. In addition, previous work demonstrated the ability of MSCs to
enhance cutaneous wound healing [258]. This versatile cell type, has been
of particular interest for the field of tissue engineering as it can be derived
from medical waste and exhibit the capability to differentiate into multiple
tissue-forming cell lineages [258]. Especially in the wound healing context
MSCs were not only demonstrated to participate in the formation of new soft
tissue, but also to modulate the inflammatory environment by eliciting M2
polarization of macrophages [259]. Although, cell-based therapies require
additional effort and increase the complexity of a material, the responsive
behavior of the MSCs might be of particular therapeutic benefit for the
generally complex wound environment.
In conclusion, this versatile hydrogel platform might act as an efficient
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system for the engineering of dysregulated wound environments. Moreover,
the proposed further experiments and additional optimization procedures
could lead to an increased general knowledge about the modulation of sig-
naling environment via biohybrid polymeric biomaterials and facilitate the
widespread medical applications of such highly tunable materials to support
the repair processes in chronic or non-healing wounds.
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SUPPLEMENTARY MATER IALS & METHODS
The following chapter contains supplementary materials and methods summariz-
ing the experimental procedures conducted by the group of Dr. Sandra Franz and
Dr. Ulf Anderegg, both from the University Leipzig, Department of Dermatology,
Venerology and Allergology.
culture of human neutrophils & monocytes
Human peripheral blood was taken from healthy volunteers after approval of
the local ethics committee in compliance with the Declaration of Helsinki.
Monocytes, inflammatory macrophages and neutrophils were generated as
previously described [193, 194]. The culture of all primary cells was per-
formed at 37°C and 5% v/v CO2 in a humidified atmosphere.
generation of conditioned medium
Conditioned medium was derived from inflammatory activated macropha-
ges or dermal fibroblasts. Therefore, macrophages were stimulated with
100 ng/ml LPS (Sigma Aldrich, Germany) in Roswell ParkMemorial Institute
1640 medium (RPMI) (Biochrom, Germany) supplemented with 2% FCS.
Dermal fibroblasts were seeded at 5x104. After overnight culture, dermal fi-
broblasts were washed twice and stimulated with 5 ng/ml TNF and 2.5 ng/ml
IL-1β (both Miltenyi Biotec, Germany) in R2 medium and further cultured.
After 24 h conditioned SN from macrophages and dermal fibroblasts were
collected and stored at -20°C until further use.
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transmigration assay
Transmigration assays were performed with freshly purified neutrophils or
monocytes. Cells were resuspended in RPMI medium and placed (2.5x104
per insert) to the upper compartment of transwell chambers (ThinCerts, pore
size of 3 µm, Greiner Bio-One, Germany). Conditioned medium from
dermal fibroblasts or controls as indicated were added to the lower well.
Neutrophils or monocytes were allowed to migrate at 37°C and 5% v/v CO2
in a humidified atmosphere for 30 min and 2 h, respectively. Migrated cells
in the lower wells were quantified by counting the cells microscopically.
murine wound healing study
Animal experiments were performed in accordance with institutional and state
guidelines and approved by the Committee on Animal Welfare of Saxony
(TVV 24/12). C57BL/6 mice (10-12 weeks old) were anesthetized and full
thickness (including panniculus carnosus) wounds were inflicted with 6 mm
dermal biopsy punches on both sites of the shaved back. Hydrogel discs
(5 mm) were applied to the wounds and covered with Mepitel (Mölnlycke
Health Care, Sweden) and Raucodrape (Lohmann&Rauscher, Germany) to
keep the hydrogel in place and moisturized. Five days post-wounding, mice
were sacrificed and hydrogels were recovered from the wounds, quick-frozen
in liquid nitrogen and stored at -80°C until quantification for bound wound-
derived mediators. Wounds were harvested and prepared as single cell suspen-
sion by enzymatic digestion with 26 U/ml Liberase DL (Roche Diagnostics,
Germany) for 30 min at 37°C and 5% v/v CO2. Digested wound tissue was
washed twice and filtered through cell strainers of different pore size (70 µm,
40 µm, Greiner Bio-One, Germany). Obtained single cell suspension was
subsequently analyzed by flow cytometry. As reference single cell suspensions
from unwounded skin that were taken from the shaved back of control mice
was prepared.
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elisa
Cytokine concentrations in the wound tissue were analyzed by ELISA as
described in Chapter 3.
flow cytometry of wound cell isolates
Single cell suspensions from wounds and unwounded skin were labeled with
murine fluorochrome-conjugated mAb using the following 5-color panel:
CD45-PerCP/Cy5.5, CD11b-PE/Cy7, Ly-6G-FITC, Ly6C-Alexa 647 (all
BioLegend, USA) and F4/80-PE (serotec, Germany). A corresponding multi-
colour panel of matching isotype antibodies was used as control. Staining with
antibodies was performed for 30 min at 4°C. After washing, cells were stained
with Zombie NIR (Biolegend, USA) to label dead cells and immediately an-
alyzed. Flow cytometry was performed on a FACS Canto II (BD, Germany).
Data were analyzed with FACS-Diva software (BD, Germany)
detection of wound-derived mediator in hydrogels
Hydrogels recovered from 5 days old wounds were immersed in 450 µl PBS
(Biochrom, Germany) and mechanically disrupted in a bead mill (TissueLyser
LT, Germany) to harvest sequestered cytokines and determine their concen-
tration by ELISA.
cell culture of human fibroblasts
Primary human dermal fibroblasts from healthy breast skin or foreskin were
isolated as previously described [260] by dispase II (Roche Diagnostics, Ger-
many) mediated removal of the epidermal sheet and digestion of the dermal
compartment with collagenase (Sigma Aldrich, Germany). The investigations
were approved by the local ethics committee and conducted according to the
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Declaration of Helsinki Principles. To remove tissue debris the cell suspension
was passed through 70 µm filters (BD Biosciences, Germany). Cells were
cultured with DMEM medium (Biochrom, Germany) supplemented with
10% FCS (Biochrom) and 1% penicillin/streptomycin (PAA Laboratories,
Austria) at 37°C, 5% CO2 until confluence. For experiments cells between
passages 2–-4 were used and if not mentioned otherwise dermal fibroblasts
were detached by 0.05% trypsin/0.02% EDTA (Biochrom).
For growth on starPEG-heparin hydrogels, either FibroLife Basal medium
(Cell Systems, Germany) supplemented with FibroLife Serum Free LifeFactor
Kits (containing 500 µg/ml of human serum albumin, 0.6 µm linoleic acid,
0.6 µg/ml lecithin, 5 ng/ml rhFGF2, 5 ng/ml rhEGF, 30 pg/ml rhTGF-β,
50 µg/ml ascorbic acid, 7.5 mM l-glutamine and 1.0 µg/ml hydrocortisone
hemisuccinate as final concentrations) or DMEM supplemented with 5%
FCS and antibiotics were used as indicated. The day before seeding of the
dermal fibroblasts on hydrogels, the cells were conditioned with synthetic
medium.
preparation of collagen-coated matrices
Collagen-coated tissue culture substrates were generated by in vitro fibril-
logenesis of collagen from calf skin (Collagen A, Biochrom) according to
manufacturer’s instructions.
attachment assay
1.5x104 cells were seeded on each hydrogels-coated coverslips placed in 24-
well format and incubated for 6, 24 and 48 h in synthetic medium. Attached
cells were fixed using 4% paraformaldehyde for 20 min at room temperature
(RT) and washed with PBS 3 times. Cell nuclei were counterstained with 4’-
6-Diamidino-2-phenylindole (DAPI) (0.1 µg/ml, Sigma–Aldrich) for 10 min
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at RT on hydrogels that had been incubated for 6 h and 48 h. Numbers of cell
stained by DAPI were counted in 10 microscopic fields with 100 fold mag-
nification on hydrogels by using BZ-9000E microscope and corresponding
software BZ-II Viewer, BZ-II Analyzer (Keyence, Germany).
visualization of decellularized ecm
Dermal fibroblasts were seeded at a density of 1x104 cells on each hydrogel-
coated coverslip, placed in 24-well format and incubated for 7 days in DMEM
supplemented with FCS, cellshield-antibiotic agent (all Biochrom) and ascor-
bic acid (Sigma, 50 µg/ml).Cell growth was inspected by phase contrast
microscopy (Keyence). Medium (in part with TGF-β (10 ng/ml) was replaced
every 3rd day. At day 7 the coverslips were moved to empty wells and
decellularized according Castelló-Cros and Cukierman [261]. Briefly, after
gently washing with PBS the cells were lysed with a buffer containing of
PBS, Triton X100 (1%) and NH4OH (0.05 M). After final wash steps
the remaining extracellular matrix was fixed with 4% paraformaldehyde for
20 min at RT and washed with PBS 3 times. The matrix proteins were
visualized either with Sirius Red (Sirius Red/Fast Green Collagen Staining Kit,
AmsBio, Germany) or by immunofluorescence staining with anti-collagen
I antibody (ab138492, abcam) and anti-fibronectin antibody (IST9, Santa
Cruz Biotech). Goat-anti-mouse-Alexa647 and goat-anti-rabbit Alexa546
(both Thermo Scientific, Germany) were used as secondary antibodies.
proliferation assay
Cell proliferation was measured by using XTT assay (Roche Diagnostics,
Germany) according to the manufacturer’s instructions. 5x104 cells/well were
seeded into 24 wells plates containing starPEG-coated or collagen coated
coverslips (12 mm diameter). After 24 h of growth the coverslips were
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transferred into a new plate where also the tissue culture plastic control cells
were grown. The transfer ensured that only cells growing on the respective
substrates were measured. After total 48 h of culture XTT labeling reagent
with electron coupling reagentmixture was added to each wells, and incubated
for 45 min. The absorbance of the samples was measured at 490 nm vs. cell-
free matrix containing controls using a plate reader (Synergy HT, Germany).
degradation assay
1.5x104 cells were seeded on hydrogel-coated coverslips containing 1% Atto
488 (ATTO-TEC, Germany) labeled heparin cross-linked in the scaffold
and incubated for 72 h synthetic medium. Dermal fibroblasts were fixated
and stained as described. Analysis was performed using a Leica TCS SP5
fluorescence microscope with the corresponding software.
induction of myofibroblast differentiation
Dermal fibroblasts (4x104 cells per hydrogel) were cultured on starPEG
hydrogels for 48 or 72 h with DMEM/5% FCS/1% Penicillin/Streptomycin
(Biochrom) at 37°C either untreated, or with TGF-β either added to the
culture medium (10 ng/ml, Peprotech) after cell seeding, or in the presence of
aECM-adsorbed TGF-β (250 ng/gel), adsorbed as described below. Collagen-
coated slides were used as control.
immunofluorescence staining
1.5x104 cells were seeded on hydrogel-coated coverslips and incubated for
72 and 96 h in synthetic medium with or without soluble TGF-β induction
(10 ng/ml, Peprotech, Germany). Dermal fibroblasts were fixed by 4% para-
formaldehyde for 20 min and washed with PBS. For detection of intracellular
proteins, cells were permeabilized with PBS, 1% Tween 20 for 10 min at RT.
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After blocking with PBS containing 3% BSA the following antibodies and
reagents were used for immunofluorescence staining: anti-α-SMA (1.0 µg/ml,
Sigma–Aldrich), anti-collagen I (0.67 µg/ml, Sigma–Aldrich), Alexa Fluor-
488- or TRITC-Phalloidine (0.17 µg/ml, Cell Signaling, Leiden, The Nether-
lands) and DAPI. Additionally, anti-Palladin (Proteintech, 10853-1-AP, UK)
was used to detect TGF-β-mediated activation of dermal fibroblasts via co-
localization of this actin bundling protein with actin fibers. Anti-rabbit Alexa
647 (Thermo Scientific) was used as a secondary antibody for anti-Collagen
I and anti-palladin. Control gels stained only with secondary antibodies
were photographed under identical conditions. Analysis was performed us-
ing a BZ9000E fluorescence microscope with the corresponding software
(Keyence).
gene expression analysis in human cells
Gene expression in dermal fibroblasts was analyzed as described in Chapter 3.
In contrary, the analysis was performed with a Rotor-Gene Q cycler (Qiagen,
Germany). The primers (Tab. 5, Page 120) were designed and verified with
HUSAR software package (EMBL, Germany) and synthesized by Metabion
International AG (Germany).
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NOMENCLATURE
γ molar ratio of starPEG to heparin
ANOVA analysis of variance
ATCC American Type Culture Collection
Arg1 arginase 1
BMP2 bone morphogenetic protein 2
BSA bovine serum albumin
CL MMP-cleavable peptide linkers
Chil3 chitinase-like 3
DMEM Dulbecco’s modified eagle medium
ECM extracellular matrix
EDC 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide
EGF endothelial growth factor
ELISA enzyme-linked immunosorbent assay
FCS fetal calf serum
FGF-1 fibroblast growth factor 1
FGF-2 fibroblast growth factor 2
FGF-7 fibroblast growth factor 7
GAG glycosaminoglycan
HRP horseradish peroxidase
HS heparan sulfate
IFN γ interferon gamma
IGF1 insulin-like growth factor 1
IL-1β Interleukin 1β
IL-10 Interleukin 10
IL-13 Interleukin 13
IL-1RA Interleukin 1 receptor antagonist
IL-4 Interleukin 4
IL-6 Interleukin 6
IL-8 Interleukin 8
IMDM Iscove’s Modified Dulbecco’s Medium
KD equilibrium dissociation constant
LPS lipopolysaccharide
M molar mass
M-CSF macrophage colony-stimulating factor
MCP-1 monocyte chemoattractant protein 1
(CCL2)
MIP-1 α macrophage Inflammatory Protein-1
α (CCL3)
MMP matrix metalloproteinase
MSC mesenchymal stem cell
NETs neutrophil extracellular traps
PBS phosphate buffered saline
PDGF platelet-derived growth factor
PE phycoerythrin
PE polyethylene
PEG poly(ethylene glycol)
PEMA poly(ethylene-alt-maleic anhydride)
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nomenclature
PET polyethylene terephthalate
PFA paraformaldehyde
PI propidium iodide
PLA polylactic acid
PMMA poly(methyl methacrylate)
PMN polymorphonuclear netrophil
PP polypropylene
PSU polysulfone
PTFE polytetrafluoroethylene
PU polyurethane
R2 Coefficient of determination
RANTES regulated on activation normal
T-cell expressed and secreted (CCL5)
Rg radius of gyration
RPMI Roswell Park Memorial Institute 1640
medium
S-NHS N-Hydroxysulfosuccinimide
SDF-1 stromal cell-derived factor 1
α-SMA α-smooth muscle actin
TGF-β transforming growth factor β
TIME guideline for wound bed preparation
TIMP tissue inhibitor of metalloproteinase
TMB tetramethylbenzidine
TNF tumor necrose factor
VEGF vascular endothelial growth factor
pHEMA polyhydroxyethylmethacrylate
v/v volume/volume
w/v weight/volume
w/v weight/weight
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